Previous Article | Next Article 
Microbiology and Molecular Biology Reviews, June 2004, p. 320-344, Vol. 68, No. 2
1092-2172/04/$08.00+0 DOI: 10.1128/MMBR.68.2.320-344.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
ERK and p38 MAPK-Activated Protein Kinases: a Family of Protein Kinases with Diverse Biological Functions
Philippe P. Roux* and
John Blenis
Department
of Cell Biology, Harvard Medical School, Boston, Massachusetts
02115

SUMMARY
Conserved signaling pathways that activate the mitogen-activated
protein
kinases (MAPKs) are involved in relaying extracellular
stimulations
to intracellular responses. The MAPKs
coordinately regulate
cell proliferation, differentiation, motility,
and survival,
which are functions also known to be mediated by members
of
a growing family of MAPK-activated protein kinases (MKs;
formerly
known as MAPKAP kinases). The MKs are related
serine/threonine
kinases that respond to mitogenic and stress stimuli
through
proline-directed
phosphorylation and activation of
the kinase
domain by extracellular signal-regulated kinases 1 and 2 and
p38
MAPKs. There are currently 11 vertebrate MKs in five
subfamilies
based on primary sequence homology: the ribosomal S6
kinases,
the mitogen- and stress-activated kinases, the
MAPK-interacting
kinases, MAPK-activated protein
kinases 2 and 3, and MK5. In
the last 5 years, several MK substrates
have been identified,
which has helped tremendously to identify the
biological role
of the members of this family. Together with data from
the study
of MK-knockout mice, the identities of the MK substrates
indicate
that they play important roles in diverse biological
processes,
including mRNA translation, cell proliferation and
survival,
and the nuclear genomic response to mitogens and cellular
stresses.
In this article, we review the existing data on the MKs and
discuss
their physiological functions based on recent
discoveries.

INTRODUCTION
Cells recognize and respond to extracellular stimuli by engaging
specific
intracellular programs, such as the signaling cascade
that
leads to activation of the mitogen-activated protein kinases
(MAPKs).
All eukaryotic cells possess multiple MAPK
pathways, which coordinately
regulate diverse cellular activities
running the gamut from
gene expression, mitosis, and metabolism to
motility, survival
and apoptosis, and
differentiation. To date, five distinct groups
of MAPKs have
been characterized in mammals: extracellular signal-regulated
kinases
(ERKs) 1 and 2 (ERK1/2), c-Jun amino-terminal kinases
(JNKs)
1, 2, and 3, p38 isoforms

, ß,

, and

, ERKs 3 and
4, and ERK5 (reviewed in references
25 and
103). Since
Saccharomyces cerevisiae possesses six different
MAPKs, the relative complexity
of the human genome suggests
that there are probably several
additional vertebrate MAPK
subfamilies (
118). The
most extensively
studied groups of vertebrate MAPKs to date
are the ERK1/2, JNKs,
and p38 kinases.
MAPKs
can be activated by a wide variety of different stimuli,
but in general, ERK1 and ERK2 are preferentially activated in response
to growth factors and phorbol esters, while the JNK and p38 kinases are
more responsive to stress stimuli ranging from osmotic shock and
ionizing radiation to cytokine stimulation (reviewed in reference
147) (Fig.
1). Although each MAPK has unique characteristics, a number of
features are shared by the MAPK pathways studied to date. Each
family of MAPKs is composed of a set of three evolutionarily
conserved, sequentially acting kinases: a MAPK, a
MAPK kinase (MAPKK), and a MAPKK
kinase (MAPKKK). The MAPKKKs, which are
serine/threonine kinases, are often activated through
phosphorylation and/or as a result
of their interaction with a small GTP-binding protein of the Ras/Rho
family in response to extracellular stimuli
(36,
98). MAPKKK
activation leads to the
phosphorylation and activation of a
MAPKK, which then stimulates MAPK activity through
dual phosphorylation on threonine
and tyrosine residues located in the activation loop of kinase
subdomain VIII. Once activated, MAPKs phosphorylate target
substrates on serine or threonine residues followed by a proline;
however, substrate selectivity is often conferred by specific
interaction motifs located on physiological substrates.
Furthermore, MAPK cascade specificity is also mediated through
interaction with scaffolding proteins which organize pathways in
specific modules through simultaneous binding of several
components.
The wide range of functions of the MAPKs are
mediated through
phosphorylation of
several substrates, including phospholipases,
transcription factors,
and cytoskeletal proteins. MAPKs also
catalyze the
phosphorylation and activation of
several protein
kinases, termed MAPK-activated protein kinases
(MKs), which
represent an additional enzymatic and amplification step
in
the MAPK catalytic cascades. The MK family comprises the

90-kDa
ribosomal S6 kinases (RSKs), the mitogen- and
stress-activated
kinases (MSKs), the MAPK-interacting
kinases (MNKs), MAPK-activated
protein kinases 2 and 3 (MK2
and -3, formally termed MAPKAP-K2
and -3), and
MAPK-activated protein kinase 5 (MK5, formally
termed
MAPKAP-K5). The MKs are related kinases that mediate
a wide
range of biological functions in response to mitogens
and stress
stimuli. Because of the lack of specific inhibitors
against these
kinases, it has been a challenge to dissect their
exact biological
functions and to differentiate those from direct
MAPK
functions. This review will address our current understanding
of the
properties, structure, and regulation of the MKs and
discuss their
physiological functions based on studies with
knockout mice and
recently identified
substrates.

MAPK FAMILIES
ERK1/2 Module
Properties.
The
mammalian ERK1/2 module, also known as the classical mitogen
kinase
cascade, consists of the MAPKKKs A-Raf, B-Raf, and
Raf-1,
the MAPKKs MEK1 and MEK2, and the MAPKs ERK1
and ERK2 (Fig.
1). ERK1
and ERK2 have 83% amino acid identity and are expressed
to
various extents in all tissues (reviewed in reference
25).
They are strongly
activated by growth factors, serum, and phorbol
esters and to a lesser
extent by ligands of the heterotrimeric
G protein-coupled receptors,
cytokines, osmotic stress, and
microtubule disorganization
(
112). MEKK1/2/3 and
c-Mos kinases
are also known to act as MAPKKKs in this
pathway. While the
proto-oncogene c-
mos appears to play an
important role during
meiosis, gene disruption studies suggest that
MEKK1/2/3 may
have limited impact on or redundant contributions to
activation
of the ERK1/2 pathway
(
238,
242).
Activation mechanisms.
Typically, cell surface
receptors such as tyrosine kinases (RTK) and G protein-coupled
receptors transmit activating signals to the Raf/MEK/ERK cascade
through different isoforms of the small GTP-binding protein Ras
(reviewed in references
19 and
234). Activation of
membrane-associated Ras is achieved through recruitment of SOS (son of
sevenless), a Ras-activating guanine nucleotide exchange factor. SOS
stimulates Ras to change GDP to GTP, allowing it to interact with a
wide range of downstream effector proteins, including isoforms of the
serine/threonine kinase Raf
(63). The exact mechanism
of Raf activation is still elusive but is known to require Ras binding
as well as multiple phosphorylation
events at the membrane (reviewed in reference
28). Regulation of both
Ras and Raf is crucial for the proper maintenance of cell
proliferation, as activating mutations in these genes lead to
oncogenesis (28). Indeed,
Ras has been shown to be mutated in 30% of all human cancers,
while B-Raf is mutated in 60% of malignant melanomas (reviewed
in references 42 and
125). Activated Raf
binds to and phosphorylates the dual specificity kinases MEK1 and -2,
which in turn phosphorylate ERK1/2 within a conserved Thr-Glu-Tyr (TEY)
motif in their activation loop. Amplification through the signaling
cascade is such that it is estimated that activation of solely
5% of Ras molecules is sufficient to induce full activation of
ERK1/2 (71).
In
S. cerevisiae, the MAPK modules are neatly organized
by scaffolding proteins that ensure efficiency and specificity in the
signaling cascades
(226). The yeast
scaffolding protein Ste5p selectively binds a MAPKKK (Ste11p),
a MAPKK (Ste7p), and a MAPK (Fus3p) and couples them
to their upstream activators. In mammals, no homologues of Ste5p have
yet been identified, but the scaffolding protein JIP-1 appears to have
similar functions in the JNK cascade of vertebrates (reviewed in
reference 103). Several
proteins have been shown to interact with members of the ERK cascade,
including the scaffold proteins MP-1 and KSR and the modulators CNK and
RKIP, resulting in stimulation or inhibition of the ERK1/2
cascade (reviewed in reference
148).
Substrates and functions.
ERK1/2 are distributed
throughout quiescent cells, but upon stimulation, a significant
population of ERK1/2 accumulates in the nucleus
(24,
66,
111). While the
mechanisms involved in nuclear accumulation of ERK1/2 remain elusive,
nuclear retention, dimerization,
phosphorylation, and release from
cytoplasmic anchors have been shown to play a role (reviewed in
reference 152). ERK1/2
signaling has been implicated as a key regulator of cell proliferation,
and for this reason, inhibitors of the ERK pathway are entering
clinical trials as potential anticancer agents
(97). Two structurally
unrelated compounds are commonly used to specifically
inhibit the ERK1/2 pathway in cultured cells. Both
U0126 and PD98059 are noncompetitive inhibitors of MEK1/2/5 and prevent
stimulation-mediated activation of ERK1/2/5 (reviewed in reference
3) (Fig.
1).
Activated ERK1
and ERK2 phosphorylate numerous substrates in all cellular
compartments, including various membrane proteins (CD120a, Syk, and
calnexin), nuclear substrates (SRC-1, Pax6, NF-AT, Elk-1,
MEF2, c-Fos, c-Myc, and STAT3), cytoskeletal proteins
(neurofilaments and paxillin), and several MKs (reviewed in reference
25). RSKs, MSKs, and MNKs
represent three kinase subfamilies of ERK1/2
substrates. While MSKs and MNKs have been shown to be
activated by both the ERK1/2 and p38 pathways, RSK family members are
exclusively activated by the ERKs
(56). These
ERK1/2-activated kinases will be discussed
in greater detail
below.
p38 MAPK Module
Properties.
p38 (also known as CSBP, mHOG1, RK, and SAPK2) is
the archetypal
member of the second MAPK-related
pathway in mammalian cells
(
73,
108).
The p38 module
consists of several MAPKKKs, including MEKKs
1 to 4,
(MEKK1-4), MLK2 and -3, DLK, ASK1, Tpl2 (also termed
Cot), and Tak1,
the MAPKKs MEK3 and MEK6 (also termed MKK3 and
MKK6,
respectively), and the four known p38 isoforms (

, ß,

,
and

) (Fig.
1) (reviewed in reference
103). p38

has
50% amino
acid identity with ERK2 and bears significant homology
to the
product of the budding yeast
hog1 gene, which is
activated in
response to hyperosmolarity
(
73,
108,
163). In mammalian
cells,
the p38 isoforms are strongly activated by environmental
stresses
and inflammatory cytokines but not appreciably by
mitogenic
stimuli. Most stimuli that activate p38 also activate JNK,
but
only p38 is inhibited by the anti-inflammatory drug SB203580,
which
has been extremely useful in delineating the function
of p38
(
108).
Activation mechanisms.
MEK3 and MEK6 are activated by
a plethora of MAPKKKs which become activated in response to
various physical and chemical stresses, such as oxidative stress, UV
irradiation, hypoxia, ischemia, and various cytokines, including
interleukin-1 (IL-1) and tumor necrosis factor alpha (reviewed in
reference 25). MEK3 and
MEK6 show a high degree of specificity for p38, as they do not activate
ERK1/2 or JNK. MEK4 (also known as MKK4 and Sek1) is a known JNK kinase
that possesses some MAPKK activity toward p38, suggesting that
MEK4 represents a site of integration for the p38 and JNK pathways
(14,
123). While MEK6
activates all p38 isoforms, MEK3 is somewhat selective, as it
preferentially phosphorylates the p38
and p38ß
isoforms. The specificity in p38 activation is thought to result from
the formation of functional complexes between MEK3/6 and different p38
isoforms and the selective recognition of the activation loop of p38
isoforms by MEK3/6 (47).
Activation of the p38 isoforms results from the MEK3/6-catalyzed
phosphorylation of a conserved
Thr-Gly-Tyr (TGY) motif in their activation loop. The structures of
inactive and active
(phosphorylated) p38
have
been solved by X-ray crystallography. The
phosphorylated TGY motif and the
length of the activation loop were found to differ in ERK2 and JNK,
which likely contributes to the substrate specificity of p38
(219,
230).
Substrates and functions.
p38 was shown to be present
in both the nucleus and cytoplasm of quiescent cells, but upon cell
stimulation, the cellular localization of p38 is not well understood.
Some evidence suggests that, following activation, p38 translocates
from the cytoplasm to the nucleus
(156), but other data
indicate that activated p38 is also present in the cytoplasm of
stimulated cells
(6).
A large body of
evidence indicates that p38 activity is critical for normal immune and
inflammatory responses. p38 is activated in macrophages, neutrophils,
and T cells by numerous extracellular mediators of inflammation,
including chemoattractants, cytokines, chemokines, and bacterial
lipopolysaccharide
(143). p38 participates
in macrophage and neutrophil functional responses, including
respiratory burst activity, chemotaxis, granular exocytosis, adherence,
and apoptosis, and also mediates T-cell
differentiation and apoptosis by regulating gamma
interferon production
(143). p38 also
regulates the immune response by stabilizing specific cellular
mRNAs involved in this process. For instance, with SB203580
and constitutively active forms of p38 and MEK3/6, it has been shown
that p38 regulates the expression of many cytokines, transcription
factors, and cell surface receptors
(143).
While the
exact mechanisms involved in p38 immune functions are starting to
emerge, activated p38 has been shown to phosphorylate several cellular
targets, including cytosolic phospholipase A2, the
microtubule-associated protein Tau, and the transcription factors ATF1
and -2, MEF2A, Sap-1, Elk-1, NF-
B, Ets-1, and p53
(103). p38 also
activates several MKs, including MSK1 and -2, MNK1 and -2, and MK2 and
-3, which will be discussed in greater detail
below.
JNK Module
Properties.
The first
member of the JNK family was originally isolated from
rat livers
injected with cycloheximide
(
104). JNK1, JNK2, and
JNK3
(also known as SAPK

, SAPK

, and
SAPKß, respectively)
exist in 10 or more different
spliced forms and are ubiquitously
expressed, although JNK3
is present primarily in the brain.
The JNKs are strongly
activated in response to cytokines, UV
irradiation, growth factor
deprivation, DNA-damaging agents,
and, to a lesser extent, some G
protein-coupled receptors, serum,
and growth factors
(
103).
Activation mechanisms.
Like ERK1/2 and p38, JNK
activation requires dual
phosphorylation on tyrosine and
threonine residues within a conserved Thr-Pro-Tyr (TPY) motif. The
MAPKKs that catalyze this reaction are known as MEK4 and MEK7,
which are themselves phosphorylated
and activated by several MAPKKKs, including MEKK1-4, MLK2 and
-3, Tpl-2, DLK, TAO1 and -2, TAK1, and ASK1 and -2
(reviewed in reference
103) (Fig.
1).
Substrates and functions.
Like ERK1/2 and p38, the
JNKs may relocalize from the cytoplasm to the nucleus following
stimulation (127). A
well-known substrate for JNKs is the transcription factor c-Jun.
Phosphorylation of c-Jun on Ser63 and Ser73 by JNK leads to increased
c-Jun-dependent transcription (reviewed in reference
225). Several other
transcription factors have been shown to be
phosphorylated by the JNKs, such as
ATF-2, NF-ATc1, HSF-1, and STAT3
(25,
103). While some
cytoplasmic targets of JNK are known, the fact that stimulated JNK does
not exhibit exclusive nuclear localization suggests that many other
cytoplasmic substrates remain to be identified. Intriguingly, there is
currently no known JNK-activated
MK.

DOCKING INTERACTIONS IN THE MAPK CASCADES
Description of Docking Sites
D domains.
It has become apparent that efficiency and
specificity of signaling
within the MAPK cascades are partly
achieved through specialized
docking motifs present in scaffold
proteins, MAPKKs, MAPKs,
and their substrates. The

-domain in c-Jun was the first identified
motif involved in
MAPK docking
(
200), which occurs in
addition
to the transient enzyme-substrate interaction through the
active
site of the kinase. Subsequently, sequences related to the

-domain
were identified in other transcription factors,
including the
MAPK-regulated bZIP, ETS, and
MAD (reviewed in reference
180).
These domains were
called docking domains (D domains or D-boxes)
and shown to increase
substrate phosphorylation by
MAPKs. Although
D domains can sometimes be recognized by more
than one class
of MAPKs, they are thought to increase
signaling specificity.
By examining the primary sequence of the regions
involved in
MAPK docking, it was found that D domains are
characterized
by a cluster of positively charged residues surrounded by
hydrophobic
residues (reviewed in reference
202). D domains can lie
either
upstream or downstream of the phosphoacceptor site and have
been
shown to be present on many MAPK substrates, including
the
MKs. Aside from MAPK substrates, D domains have also been
identified
in many MAPK regulatory proteins, which include
upstream activating
kinases (MAPKKs), phosphatases (PTP-SL,
STEP, and MKPs), and
scaffold proteins (KSR) across
different species (reviewed in
references
48).
DEF domains.
Analysis of the
Caenorhabditis elegans ETS transcription factor LIN-1 and the
scaffold protein KSR-1 revealed the presence of a second class of
MAPK docking site that consists of the Phe-Xaa-Phe-Pro
sequence, where Xaa is any amino acid and one of the Phe
residues can also be a Tyr residue
(50,
81,
129). This domain,
termed DEF (docking site for ERK and FXFP), has been
reported to be recognized only by ERK1/2 and typically lies C-terminal
to the phosphoacceptor site. DEF domains are required for
efficient substrate phosphorylation
by ERK1/2 and have been found in many substrates of the mammalian,
C. elegans, and Drosophila melanogaster ERK1/2
orthologs (50,
82,
129). DEF and D domains
can sometimes be found on the same protein, such as for Elk-1 and KSR,
where these domains may act synergistically to strengthen MAPK
interaction.
CD and ED motifs.
While it is not clear what region of ERK1/2
interacts with DEF domains, two groups independently
identified a conserved C-terminal common docking (CD) motif outside the
catalytic domain of ERK, p38, and JNK involved in D domain
interactions (166, 200). The CD motif contains acidic and hydrophobic
residues that are necessary to establish hydrophobic and electrostatic
interactions with the positively charged and hydrophobic residues of D
domains, respectively
(48,
200). The CD motif has
been shown to mediate MAPK interactions with their upstream
activators and downstream substrates, suggesting that utilization of
the interaction motifs is heavily controlled during the MAPK
activation cascade. Interestingly, the Drosophila ERK/Rolled
sevenmaker allele is mutated in the CD domain and has been
shown to be less sensitive to
dephosphorylation, suggesting that
the CD domain may also direct binding with presently uncharacterized
ERK phosphatases
(13).
Other regions
of MAPKs have also been shown to play important roles in D
domain interactions. Similar to the CD motif, the ERK docking (ED)
motif is located opposite the MAPK active center and is
thought to regulate binding specificity
(202). Exchange of only
two residues within the ED site of ERK2 altered its binding specificity
to that of p38, rendering ERK2 capable of binding to MK3
(201). The complementary
mutations in p38 did not revert the docking specificity of
p38 for that of RSK2, suggesting that additional residues must
participate in this interaction. Accordingly, another groupidentified a docking groove near the CD and ED motifs of p38 that is
required for D domain interactions with MEF2A and MEK3b
(21). Mutations of
residues within the docking groove disrupted p38 binding to the D
domain of MEF2A, suggesting that the homologous residues in ERK1/2 and
JNK may also be involved in D domain interaction. Finally, several
laboratories have reported a role for the N-terminal domain of
MAPKs in docking specificity, but the exact requirement for
this region remains to be determined (reviewed in reference
48).
Docking Interactions with MKs
Properties.
Almost all MKs possess a docking motif of the D
domain class,
containing the sequence Leu-Xaa-Xaa-Arg-Arg followed by
one
or several basic residues (Fig.
2). This docking sequence is
necessary for ERK1/2 docking to RSKs
(
62,
165,
189) and MNK2B
(
170),
ERK1/2 and p38
binding to MSK2 (
207),
as well as p38 docking
to MK5
(
179). It is likely that
MAPK docking specificity arises
from variations in the D
domain sequence and from the potential
involvement of other
unidentified regions within the MKs. Indeed,
a recent study
demonstrated that replacement of the ERK1/2 docking
site in RSK2 with
the p38 docking site of MK2 converted RSK2
into a stress-activated
kinase in vivo (
188),
indicating that
specificity of activation results from the type of D
domain.
It has already been noted that the number of contiguous basic
residues
(Lys and Arg) correlates with MAPK specificity
(
189).
Generally,
ERK1/2-specific MKs have two contiguous basic residues,
ERK1/2- and
p38-specific MKs have three or four contiguous basic
residues,
and p38-specific MKs have four or five contiguous
basic residues
(Fig.
2).
Furthermore, the amount and location of hydrophobic
residues
within the D domain may also regulate the specificity
of the
MAPK. Indeed, the p38-activated MKs tend to have at least
two
hydrophobic residues before the stretch of basic residues
(Fig.
2). Interestingly, the CD
motif in p38 kinases also contains
more contiguous acidic residues than
ERK1/2, but mutational
analyses of these motifs and flanking sequences
are warranted
to further assess the regions responsible for ERK1/2 and
p38
specificity. Because the basic residues in D domains are clustered
and
overlap defined nuclear localization sequences (NLSs) in MSK1
and
-2, MK2 and -3, and MK5 (Fig.
2), the functional results
obtained
with D domain mutants will have to be analyzed with
caution.
Regulation of docking.
The regulation of MAPK docking to the MKs
is not well understood. Several MKs have been shown to bind to ERK1/2
and/or p38 in quiescent cells and to dissociate following cell
stimulation. For instance, RSK family members bind to ERK1/2 in
quiescent cells, but following stimulation, the complex transiently
dissociates for the duration of ERK1/2 activation
(165). In fact,
differences have even been noted between different RSK isoforms, with
RSK1 having the most regulated interaction with ERK1/2. MSK1 and -2,
MK2, and MK5 have been shown to reside in the nucleus of quiescent
cells (6,
38,
44,
149,
179). Following
stimulation, MK2 and MK5 translocate into the cytoplasm, but their
relation to p38 at this point remains elusive
(6,
179). Recent evidence
indicates that p38 docking to MK5 masks its NLS and thereby promotes
its nuclear export
(179), suggesting that
docking and localization are interrelated for MK5.
The mechanisms
involved in complex dissociation are currently unknown, but mutagenesis
analysis revealed that
autophosphorylation of a
residue located near the D domain of RSK1 was required for the
regulated release of ERK1/2
(165). MSK1
and MSK2 also contain a homologous residue near their D
domains, suggesting that these kinases may also regulate ERK1/2 and p38
docking through
autophosphorylation of
their C termini. Interestingly, MNK1 has been shown to
interact with dephosphorylated ERK2
with greater affinity
(221),
suggesting that MNK1 activation may also regulate
MAPK
docking.

MAPK-ACTIVATED PROTEIN KINASES
The MK family comprises 11 members that are
generally activated
by mitogens through the ERK1/2 kinase
cascade (RSK1, RSK2, RSK3,
RSK4, and MNK2), stress stimuli through the
p38 kinase cascade
(MK2, MK3, and possibly MK5), or both
(MSK1, MSK2, and MNK1)
(Fig.
1). Of these, the RSKs and
MSKs possess two distinct and
functional kinase domains
within the same polypeptide, termed
the N-terminal kinase domain (NTKD)
and C-terminal kinase domain
(CTKD). Conversely, the MNKs, MK2 and -3,
and MK5 have a single
kinase domain that is mostly homologous to the
CTKD of the RSKs
and MSKs (Fig.
3). All of these kinases have similar activation
loop sequences that are
targeted for
phosphor-ylation
by either
ERK1/2 or p38 (Fig.
4). Based on their sequence homologies,
the MKs can be classified into five
subgroups, the RSKs, MSKs,
MNKs, MK2 and -3, and MK5 (Fig.
5), and each subgroup will be
discussed in greater detail
below.
RSK Subfamily
Discovery.
RSK1 was the
first identified MK and was discovered in
Xenopus
laevis extracts as a kinase that
phosphorylated the 40S
ribosomal subunit
protein S6
(
49). RSK homologues are
present in most vertebrate
species and have received several
names over the years (Table
1)
but are now generally called p90 ribosomal S6 kinases (RSKs).
The RSK
family contains four human isoforms (RSK1, RSK2, RSK3,
and RSK4),
which show 73 to 80% amino acid identity (Fig.
3).
RSK-related molecules
have also been identified in
C. elegans (T01H8.1) and
D.
melanogaster (RPS6 protein kinase II), which
show about 60%
amino acid identity to RSK1
(
223), but no RSK
homologues
have been found in
S. cerevisiae to date. As
mentioned above,
the RSK homologues are particular among the
serine/threonine
kinases in that they contain two distinct and
functional kinase
domains
(
52,
91). This property is
shared by the MSKs, which
are a family of RSK cousins that will be
discussed in the following
section. The CTKD (also termed D2) of the
RSKs belongs to the
calcium- and calmodulin-dependent kinase (CaMK)
group of kinases
and is the domain most conserved in members of the MK
family
(Fig.
4). The NTKD
(also termed D1) of the RSKs belongs to the
AGC family of kinases,
which includes protein kinase A, protein
kinase C, protein kinase B
(also called Akt), and the p70 ribosomal
S6 kinases 1 and 2 (S6K1 and
S6K2). The RSKs and MSKs are the
only AGC members to be part of the MK
family based on the homology
of their NTKDs. Although S6K1 and S6K2
display substantial homology
to the NTKD of the RSKs (about 40%
amino acid identity), they
are not members of the MK family because
they lack the CTKD
of the RSKs and
MSKs.
Structure and expression.
All four human RSK isoforms have a similar structure
that consists
of two distinct kinase domains joined by a linker region
of
about 100 amino acids and N- and C-terminal ends (Fig.
3). Results
from our group
and others have elucidated the distinct roles
of both kinase domains in
RSK1 and RSK2. While the NTKD was
found to be responsible for substrate
phosphorylation, both
kinase
domains were shown to autophosphorylate on sites important
for RSK1 and
RSK2 activation (
10,
52,
217). All RSK isoforms
also
contain a C-terminally located D domain that is responsible
for
docking and activation by ERK1/2 (Fig.
3)
(
62,
189). As
mentioned
above, the D domain of the RSKs consists of Leu-Ala-Gln-Arg-Arg
(Fig.
2), where only the Leu and
Arg residues are necessary
for ERK1/2 docking
(
165). Two additional
basic residues located
C-terminal to the D domain also contribute to
ERK1/2 binding,
but their presence was not found to be essential for
activation
of RSK1
(
165). The RSK isoforms
and ERK1/2 have long been shown
to interact in cells and to dissociate
upon activation (
79,
178,
246).
We have recently
shown that RSK1 dissociates from ERK1/2 through
the
autophosphorylation of a
serine residue located near the
D domain of RSK1, providing a mechanism
for the regulated docking
of ERK1/2
(
165).
RSK1, RSK2,
RSK3, and ERK1/2 are usually present in the cytoplasm of quiescent
cells, but upon stimulation, a significant portion of these proteins
translocate to the nucleus of activated HeLa, COS-7, and HEK293 cells
(24,
111,
159,
213,
247). RSK3 is the only
human isoform to possess a potential NLS
(Lys-Lys-Xaa10-Leu-Arg-Arg-Lys-Ser-Arg) (Fig.
3), whereXaa10 is a stretch of any 10 amino acids, but it
remains unknown whether this domain is functional or if other regions
are required for nuclear translocation of the RSKs. The small death
effector domain protein PEA-15 has been shown to inhibit RSK2 nuclear
translocation, but the biological function of this interaction remains
unknown (213). Activated
RSK2 can also be found in the cytoplasm of stimulated cells, suggesting
that RSK2 substrates may exist in both nuclear and cytoplasmic
compartments (24). It
appears likely that the RSKs possess protein substrates in all cellular
compartments, including the cytosol, nucleus, and plasma membranes, and
that their localization is regulated via multiple
mechanisms.
Analysis of the expression of the RSK isoforms has
revealed differential expression patterns. Northern analysis of
rsk1 expression showed that this isoform is present in most
tissues but is expressed at higher levels in the kidney, lung, and
pancreas (243). Analysis
of rsk2 mRNA revealed that the alternative use of two
different polyadenylation sites gave rise to two transcripts of 3.5 and
8.5 kb (243). The
rsk2 and rsk3 transcripts and proteins are expressed
in most tissues, including heart, brain, placenta, liver, kidney, and
pancreas, with predominant expression in skeletal muscle
(43,
243,
247). The rsk4
transcript is also expressed ubiquitously but was shown to be present
in high levels in fetal tissues and in adult brain and kidney
(241). Northern analysis
also revealed the presence of two secondary rsk4 transcripts
(5 and 9 kb), but whether these transcripts result from alternative
splicing or alternative polyadenylation remains unknown
(241). Interestingly,
the reported mouse and rat RSK4 sequences contain an additional
N-terminal region that is not found in human RSK4 or in other RSK
family members. Since human RSK4 was originally identified
by positional cloning, this suggests that human RSK4 may also
contain this additional domain at its N terminus. However, the function
of this potentially novel domain remains to bedetermined.
Activation mechanisms.
All RSK isoforms, including
the C. elegans and D. melanogaster
homologues of RSK, contain six
phosphorylation sites that have
been shown in RSK1 and RSK2 to be responsive to mitogen stimulation
(35) (Fig.
6). Mutational analysis revealed that four of these sites (Ser221, Ser363,
Ser380, and Thr573 in human RSK1) are essential for RSK1 activation
(35) (Fig.
7). Of these, Ser363 and Ser380 are located within sequences conserved
among most AGC kinases, the turn motif and hydrophobic motif,
respectively (138).
Phosphorylation of the turn motif in RSK1 and RSK2 is essential for
kinase activity and is thought to be mediated by ERK1/2 because it is
located within a proline-directed
phosphorylation site. However,
results from our group indicate that this site is not efficiently
phosphorylated by ERK1 in vitro
(159), and alanine
substitution of Pro364 only slightly reduces mitogen-stimulated RSK1
activation (P. Roux, unpublished results), suggesting that another
kinase that does not require a proline at position +1 is able
to phosphorylate this site in vivo. Interestingly, protein kinases A
and C have been shown to autophosphorylate on the homologous site in
vivo (4), and this site is
modified by a heterologous kinase in Akt
(5,
206). It is currently
unclear which kinase(s) is responsible for phosphorylating the turn
motif in RSK isoforms, and further studies are needed to understand the
regulation of this site. Interestingly, the turn motif in protein
kinase C has been shown to act as a
phosphorylation-dependent docking
site for heat shock protein 70 (HSP70)
(61), suggesting that
Ser363 may have a similar function during RSK1
activation.
Serine/threonine kinase
3'-phosphoinositide-dependent kinase
1 (PDK1) was identified by
our group (
160) and
others (
88) as
the kinase
responsible for phosphorylation of
the activation
loop site (Ser221 in human RSK1) located in the NTKD of
the
RSKs (Fig.
7). The
hydrophobic motif in RSK1 (P. Roux, unpublished
results) and RSK2
(
57) was subsequently
shown to mediate PDK1
docking when
phosphorylated, allowing PDK1 to
phosphorylate
and activate the NTKD of RSK1 and RSK2
(
10,
35). PDK1 is required
for
the activation of many AGC kinases. For instance, mitogen
stimulation
of PDK1-null embryonic stem cells does not lead
to the activation of
either RSK1, Akt, or S6K1
(
229). Phosphorylation
of
the CTKD activation loop of the RSK isoforms is thought to be
mediated
by ERK1/2
(
195), but mutation of
this site (Thr573 in RSK1)
to alanine only partially reduces RSK1 and
RSK2 activation (
10,
29,
165).
Aside from
phosphorylating the activation loop site, ERK1/2
may also promote RSK1
activation by mediating its translocation
to the plasma membrane, where
it can be activated by membrane-associated
kinases
(
159). Indeed, recent
data suggest that the simple myristoylation
of an RSK1 mutant incapable
of binding ERK1/2 increases its
level of
phosphorylation at Ser363 and
Ser380, suggesting that
membrane translocation of the RSKs plays an
important part in
their activation process
(
159). However, the
exact domains within
RSKs that are involved in their cellular
localization before
and after stimulation remain unknown.
The
sequence of events during activation of the RSKs remains elusive, but
the mechanisms of activation are starting to emerge and appear to
require well-ordered
phosphorylation events (Fig.
7). Upon mitogen
stimulation, activated ERK1/2 is thought to phosphorylate RSK1 on
Thr573, which is partly required for CTKD activation, and possibly also
on Ser363 (turn motif) and Thr359 (site with no associated function)
(35,
165). As mentioned
above, the role of ERK1/2 in activation of the RSKs may also be to
bring the RSK isoforms into proximity with membrane-associated kinases
that phosphorylate Ser363 and/or Ser380
(159; P. Roux,
unpublished results). The activated CTKD then phosphorylates the
hydrophobic motif (Ser380) of the RSKs, which creates a docking site
for PDK1, the enzyme that phosphorylates the activation loop site
(Ser221) and thereby activates the NTKD. While the CTKD has definitely
been shown to phosphorylate Ser380
(29,
217), the involvement of
the NTKD or other kinases in the
phosphorylation of this site
remains unknown. Interestingly, the homologous site in Akt has been
shown to be potentially regulated by
autophosphorylation
(206) and by a
heterologous kinase localized to lipid rafts
(78), suggesting that the
NTKD of the RSKs or a membrane-associated kinase may also phosphorylate
the RSK isoforms at this site. Consistent with this, we have found that
a CTKD-inactive mutant of RSK1 is still partially responsive to mitogen
and phosphorylated at Ser380,
agreeing with the idea that the hydrophobic motif may be regulated by
multiple inputs (P. Roux, unpublished results).
The importance of
the hydrophobic motif in activation of the RSKs was recently
underscored by the identification of a phosphate-binding pocket in the
kinase domain of many AGC kinases, which is used for intramolecular
interaction with their own
phosphorylated hydrophobic motif
(55). This interaction
was shown to induce a synergistic stimulation of RSK2 catalytic
activity, whereas mutation of the phosphate-binding pocket led to a
reduction in the overall kinase activity of RSK2. PDK1 also contains
such a binding motif in its kinase domain but does not have a
hydrophobic motif. Using embryonic stem cells with a knock-in mutation
in the phosphate-binding pocket of PDK1, Alessi and colleagues have
recently shown that the binding pocket in PDK1 is essential for
activation of RSK2, S6K1, and SGK, suggesting that PDK1
uses this motif to interact with the
phosphorylated hydrophobic motif of
these kinases (34).
Finally, RSK1 activity has been shown to be
regulated through its interaction with 14-3-3ß (20). 14-3-3
proteins interact with a wide variety of cellular proteins, including
protein kinases, receptor proteins, enzymes, and small G proteins,
generally through a phosphoserine-containing motif (240).
14-3-3ß binds to
phosphorylated Ser154 of RSK1 and
thereby negatively regulates its catalytic activity
(20). Mutation of Ser154
to alanine increased both basal and serum-stimulated RSK1 activity,
indicating that 14-3-3ß normally represses RSK1 activity.
Because the RSKs have been shown to interact with their upstream
activators (ERK1/2 and PDK1), various downstream substrates, and
regulatory proteins such as 14-3-3ß and PEA-15, they appear to
function as scaffold proteins that allow multiple proteins to come
together and form a signaling
network.
Substrates and functions.
As mentioned above, RSK1 was
first discovered as a kinase that
phosphorylated the ribosomal
subunit protein S6. However, several lines of evidence indicated that
S6 is not a major physiological target of the RSKs (30; reviewed in
reference 120). Indeed,
several groups have shown that S6K1 and S6K2 were the physiological S6
kinases in somatic cells, because treatment of cells with the
mTOR (mammalian target of rapamycin) inhibitor rapamycin was
shown to fully inhibit mitogen-induced S6
phosphorylation without
affecting the activity of the RSKs
(30,
87). Thus, it is
generally thought that the RSKs may only modulate S6
phosphorylation under certain
specific cellular circumstances
(120).
The
important physiological roles played by the RSKs have been underscored
by the discovery that defects in the rsk2 gene are the cause
of Coffin-Lowry syndrome (Table
1). Coffin-Lowry syndrome
is an X-linked dominant disorder characterized by psychomotor and
growth retardation and facial, hand, and skeletal malformations
(84,
210). Numerous mutations
have now been identified in the rsk2 gene, most of which are
predicted or have been shown to result in truncated or inactive RSK2
proteins (40,
83). Fibroblasts derived
from Coffin-Lowry syndrome patients have been useful in determining the
function of RSK2 with respect to this human disease; however,
differences found between these cells and RSK2-deficient mouse
fibroblasts suggest that Coffin-Lowry syndrome may be a multivariable
disease and may not be the ideal system with which to study RSK2
function. Both the rsk2 and rsk4 genes are located on
chromosome X, and recent data also implicate rsk4 in
nonspecific X-linked mental retardation (Table
1), but definitive
evidence remains to be provided for rsk4
(241).
The
substrate specificity of RSK1 for target
phosphorylation has been determined
with synthetic peptide libraries and found to require the minimum
sequences Arg/Lys-Xaa-Arg-Xaa-Xaa-pSer/Thr or Arg-Arg-Xaa-pSer/Thr,
where pSer is phosphoserine/phosphothreonine(110). These analyses
also revealed that RSK1 prefers to phosphorylate Ser rather than Thr
residues by a factor of about 5, and consistent with this, the majority
of RSK1 and RSK2 substrates found to date are
phosphorylated on Ser residues. A
number of RSK functions can be deduced from the nature of their
substrates, and data from many groups point towards roles for the RSKs
in transcriptional regulation, cell cycle regulation, and cell survival
(Fig.
8). Although more substrates have been identified for RSK2, most studies
have not determined whether the other RSK isoforms could also
phosphorylate the same targets, indicating that many currently known
substrates may be shared by different RSK family
members.
(i) Transcriptional regulation by RSK.
Immediately after their activation
and translocation, the RSKs
and the ERKs are capable of phosphorylating
multiple transcription
factors that contribute to the induction of
immediate-early
(IE) genes (reviewed in reference
205). For example, the
transcription
factors serum response factor (SRF)
(
15,
161) and CREB (cAMP
response
element-binding protein)
(
12,
65,
239) and possibly the
chromatin-associated
histone H3
(
168) are substrates of
the RSKs that participate
in the immediate-early response. Many
immediate-early gene products,
such as c-Fos
(
22), c-Jun
(
24), and Nur77
(
52), are also
phosphorylated
by the RSKs,
providing a dual mechanism of immediate-early gene
control. The
posttranslational modification of these immediate-early
gene products
depends upon sustained RSK activation. Indeed,
extensive evidence has
been presented supporting a model in
which certain immediate-early gene
products can act as molecular
sensors for ERK and RSK nuclear
localization, signal duration,
and signal strength
(
128,
129). For example, after
mitogen-stimulated
synthesis of c-Fos, ERK1/2 and RSK proteins are
known to phosphorylate
two Ser residues in the extreme C terminus of
c-Fos (
22).
Phosphorylation
of c-Fos by ERK1/2 and RSKs enhances its stability,
promotes
further phosphorylation
events, and increases its growth-promoting
effects
(
23,
129,
141). This
hyperphosphorylation of c-Fos
occurs
only when the activation of RSK and ERK proteins is sustained
(
128,
129).
Several
kinases phosphorylate CREB at Ser133, including protein kinase A, Akt,
and MSK1/2, but a controversial report taking advantage of Coffin-Lowry
syndrome patient-derived fibroblasts indicated that RSK2 was the major
CREB kinase activated by epidermal growth factor
(39). In these cells,
epidermal growth factor failed to increase transcription of the
c-fos gene, which was suggested to result from altered
CREB-mediated transcription
(39). To gain better
insight into the physiological role of RSK2, mice deficient in RSK2
that were generated by homologous recombination yielded slightly
different results (15).
While transcription of the c-fos gene was also altered in
fibroblasts derived from RSK2-null mice, CREB
phosphorylation was found to be
normal following platelet-derived growth factor and IGF-1stimulation (15).
Although stimulation of Elk-1
phosphorylation was unaltered in
either human or mouse RSK2-deficient cells, the transcriptional
activity of both Elk-1 and serum response factor was reduced in mouse
cells, suggesting that altered c-fos transcription may in fact
result from defects in the activation of Elk-1 and SRF
(15).
Differences
between the human and mouse models may be due to species-specific
compensation for the loss of RSK2 by other RSK isoforms, and for this
reason, mice deficient in RSK2 may not be the ideal model for
Coffin-Lowry syndrome. Unlike Coffin-Lowry syndrome patients,
RSK2-deficient mice do not display any major cerebral
abnormalities, suggesting that Coffin-Lowry syndrome may
result from several mutations affecting normal brain
development, which include RSK2 inactivation
(15). However, it was
recently demonstrated that RSK2-deficient mice may have impaired
learning abilities (43),
but the exact role of RSK2 in mouse brain development and whether these
mice can be used as a partial model for Coffin-Lowry syndrome remains
to be determined.
RSK1 also interacts with the ETS transcription
factor ER81 and enhances ER81-dependent transcription by
phosphorylating Ser191 and Ser216
(236). ER81 performs
many essential functions in homeostasis, signaling response, and
development, implying that RSK1 is also involved in these processes.
The transcription initiator factor TIF-1A also becomes
phosphorylated by ERK1/2 and RSK2
following serum stimulation on two Ser residues that are important for
TIF-1A function (245).
TIF-1A is required for RNA polymerase I transcription and rRNA
synthesis, suggesting that RSK2 and ERK1/2 regulate transcription
initiation during growth-promoting conditions. Estrogen receptor
is an ERK1/2 substrate that becomes activated following
stimulation with growth factors. RSK1 was also shown to associate with
and to phosphorylate estrogen receptor
on Ser167, which
increases estrogen receptor
-mediated transcription
(90). Another
transcription factor, microphthalmia (Mi), has been shown to be
phosphorylated by the RSKs
(237) and has been
linked to malignant melanoma
(145). As mentioned
above, the MAPKKK B-Raf was shown to be activated in
60% of melanomas
(125), suggesting that
the RSKs may be potential therapeutic targets for the treatment of
melanomas.
Finally, stimulation of the ERK pathway promotes the
interaction between RSK1 and the transcriptional coactivator
CREB-binding protein (CBP)
(130). CBP and its
paralog p300 are large molecules that facilitate complex formation
between different components of the transcriptional machinery. RSK1
interaction with CBP was found to modulate its function
(130,
220), but the exact
outcome of this interaction remains to be determined. Ectopic
expression of the RSK1 binding region of CBP in PC12 cells inhibits
NGF-mediated transcription of c-fos and neurite
outgrowth, suggesting that RSK1 binding to CBP is important for these
processes (130).
Interestingly, CBP and p300 are known to associate with several
transcription factors also known to be RSK1 and RSK2 substrates, such
as CREB, c-Fos, c-Jun, ER81, and NF-
B, suggesting that RSK1
binding to CBP may provide a second mechanism of transcriptional
control.
(ii) RSK and cell cycle control.
In addition to contributing to
the immediate-early gene response during the
G0/G1 phase of the cell cycle, a recent report
demonstrated that RSK1 and RSK2 may promote G1-phase
progression through the
phosphorylation of the
cyclin-dependent kinase (CDK) inhibitor p27kip1.
Phosphorylation of p27kip1 by RSK1 and RSK2 was found to
promote its association with 14-3-3 and prevent its translocation to
the nucleus (59). Under
growth arrest conditions, nuclear p27kip1 negatively
regulates G1 progression by sequestering and inactivating
cyclin E- or cyclin A-CDK2 complexes. Through
phosphorylation of Thr198, which is
also recognized by Akt
(58), RSK1- and
RSK2-mediated inhibition of p27kip1 nuclear translocation
may promote G1 progression within mammalian
cells.
ERK1/2 and the RSKs may also regulate progression through
the G2 phase of the cell cycle. The role of ERK1/2 in cell
cycle regulation has been demonstrated by many groups with the
preferred model of Xenopus oocyte maturation (reviewed in
reference 131). Immature
oocytes are usually arrested in the G2 phase of the first
meiotic cell division. Addition of progesterone induces synthesis of
the MAPKKK c-Mos, which in turn activates the MAPK
cascade leading to M-phase entry and subsequent maturation to an
unfertilized egg. M-phase entry is controlled in part by Cdc2, which is
a CDK normally kept in check by dual
phosphorylation on both Thr14 and
Thr15 by the inhibitory kinase Myt1. RSK2 has been shown to be the
prominent RSK isoform in Xenopus oocytes
(8), and with this model
system, RSK2 has been shown to contribute to the control of the meiotic
cell cycle at several critical points
(174).
One
mechanism by which RSK2 participates in the progression of oocytes
through the G2/M phase of meiosis I is through
phosphorylation and inhibition of
the Myt1 kinase (144).
The importance of RSK2 is such that constitutively activated RSK2 can
mediate meiosis I entry even in the absence of progesterone or
MAPK activation
(67). RSK2 regulates
meiosis I entry by binding to and phosphorylating the C terminus of
Myt1, reducing its ability to inhibit the kinase activity of
Cdc2/cyclin B1 complexes
(144). It remains
unknown whether this mechanism is conserved in other species, but
recent efforts demonstrated that Akt can also act as a Myt1 kinase in
starfish oocytes (142).
RSK2 may also be important for progression of mammalian somatic cells
through the G2/M phase of mitosis because ERK1/2 activity
was shown to be required in synchronized NIH 3T3 fibroblasts
(235).
Another way
by which RSK2 can modulate the meiotic cell cycle in Xenopus
laevis is through mediating MAPK-mediated metaphase
II arrest, an activity known as cytostatic factor. Two groups have
found that Xenopus RSK1 and RSK2 are essential for cytostatic
factor by showing that activated RSK2 causes cytostatic factor even
when MAPK is inactive and that depletion of RSK2 from oocyte
extracts removes cytostatic factor activity
(9,
68). RSK1 was later shown
to phosphorylate and activate the kinase Bub1 in vitro, a mediator of
anaphase-promoting complex inhibition
(177), suggesting that
RSK1-mediated Bub1 activation contributes, at least in part, to
metaphase II arrest
(211).
Finally,
RSK2 also modulates the meiotic cell cycle through
phosphorylation of histone H3, a
process that requires the activation of the MAPK-RSK pathway
during oocyte maturation
(173).
MAPK-mediated histone H3
phosphorylation has been shown to
contribute to chromatin remodeling during cell cycle progression and
also results in increased transcriptional regulation of several genes
(31). Although RSK1 and
RSK2 can phosphorylate histone H3 in vitro
(173), it remains
unknown whether the RSKs or another H3 kinase, such as aurora B, can
directly phosphorylate histone H3 in this system. In mammalian cells,
RSK2 has been shown to mediate mitogen-stimulated
phosphorylation of histone H3.
Fibroblasts derived from Coffin-Lowry syndrome patients and
RSK2-deficient mouse embryonic stem cells display attenuated histone H3
phosphorylation in response to
epidermal growth factor
(168). However, recent
evidence coming from the use of MSK1 and MSK2 knockout cells is
currently casting some doubt on the physiological role of RSK2 in
histone H3 phosphorylation, and
recent attempts to reproduce the experiments in fibroblasts from
Coffin-Lowry syndrome patients have failed
(190). Indeed, a
completely normal histone H3
phosphorylation response was seen
in fibroblasts from Coffin-Lowry syndrome patients, which compromises
the major piece of evidence supporting the role of RSK2 in
mitogen-stimulated histone H3
phosphorylation
(190).
(iii) RSK promotes survival.
RSK1 and RSK2 have
also been shown to regulate survival in proliferating as well as in
differentiated cells. For example, RSK2 has been found to promote the
survival of primary cortical neurons through both
transcription-dependent and -independent mechanisms
(12). Neurotrophic
factor-stimulated RSK2 phosphorylates the
proapoptotic protein Bad on Ser112, thereby
repressing its death-promoting activity
(12). Similar regulation
of Bad phosphorylation on Ser112
was seen in a hematopoietic cell line, where RSK1-mediated survival
required Bad phosphorylation and
inactivation (184).
RSK2-mediated phosphorylation of
the transcription factor CREB on Thr133 was also found to promote the
survival of primary cortical neurons through increased transcription of
survival-promoting genes
(12,
65,
239).
RSK1
promotes the survival of hepatic stellate cells by phosphorylating
mouse C/EBPß on Thr217 in response to the hepatotoxin
CCI4
(17).Phosphorylation of Thr217 was suggested to create a functional XEVD
caspase-inhibitory box (K-phospho-T217-VD) that binds and
inhibits caspases 1 and 8, and consistent with this, the
cell-permeating tetrapeptide KE217VD was also shown to
inhibit CCI4-mediated apoptosis of
stellate cells (17).
Interestingly, phosphorylation of
this site was also shown to promote cell proliferation in response to
transforming growth factor alpha
(18), suggesting that
RSK1 may be involved in this process. Two other studies indicated that
RSK1 may also promote survival through the activation of the
transcription factor NF-
B
(64,
175). NF-
B
comprises a family of heterodimeric transcription factors that are key
regulators of a broad range of genes involved in inflammatory
responses, proliferation, and apoptosis. RSK1 was
shown to phosphorylate the NF-
B inhibitor I
B
on Ser32 (64,
175),
suggesting that RSK1 may modulate
NF-
B-dependent survival and
proliferation.
(iv) Other targets of RSK.
In addition to transcriptional
regulators and cell cycle controllers, the RSKs have been shown to
phosphorylate many other targets involved in diverse cellular
processes. Upon metabotropic glutamate receptor activation, RSK1
phosphorylates several protein targets within polyribosomes, including
the known RSK1 substrate glycogen synthase 3ß (GSK3ß)
(1,
196). Phosphorylation of
GSK3ß on Ser9 by RSK1 inhibits its kinase activity and results
in increased protein translation through the release of inhibition
of the GSK3ß-regulated translation initiation factor
eIF2B (reviewed in reference
33). RSK2 also
phosphorylates another downstream substrate, the
Na+/H+ exchanger isoform 1
(NHE-1) (198). NHE-1 is
a key member of a family of exchangers that regulate intracellular pH
and cell volume (197).
RSK2-mediated phosphorylation of
NHE-1 on Ser703 was found to regulate mitogen-dependent
Na+/H+ exchange and intracellular
pH (198).
The
tumor suppressor LKB1 (also known as STK11), which is mutated in
Peutz-Jeghers syndrome, represents another
phosphorylation target of RSK2
(167). LKB1 was recently
shown to phosphorylate and activate at least 12 protein kinases of the
AMP-activated protein kinase subfamily
(115,
181). Phosphorylation of
LKB1 on Ser431 by RSK2 did not affect its activity, membrane
association, or prenylation but was found to be necessary for
LKB1-mediated growth suppression through unknown mechanisms
(167). As LKB1 is likely
an important player regulating cell proliferation, it will be
interesting to determine the mechanisms involved in RSK2-mediated
modulation of its function.
RSK2 was also shown to phosphorylate
the cell adhesion molecule L1 on Ser1152
(232). L1 is a
phosphoprotein that becomes
hyperphosphorylated during periods
of high neuronal activity, suggesting the involvement of RSK2 in
neurite outgrowth. Recently, RSK1 was suggested to play a role in
membrane ruffling, as the cytoskeleton-associated protein filamin A was
found to be phosphorylated on
Ser2152 by RSK1 (233).
Ser2152 was previously shown to be
phosphorylated by PAK1 and to be
necessary for membrane ruffling in response to PAK1 activation
(212), suggesting that
RSK1 may play a similar role in cytoskeletal
reorganization.
Proper regulation of the Ras/ERK pathway through
phosphorylation-mediated
negative feedback has been demonstrated to occur at
many levels, including Ras, Raf-1, and MEK1 and -2
(19,
28). Despite having lower
ERK1/2 protein levels, fibroblasts from RSK2-deficient mice display
higher and more sustained
phosphorylation of ERK1/2 in
response to exercise and insulin
(43), suggesting that
RSK2 inhibits the ERK1/2 signaling cascade. A possible mechanism by
which RSK2 can do this is through
phosphorylation of SOS (and
possibly Raf-1) in response to epidermal growth factor treatment
(41,
94). RSK2 would therefore
prevent further activation of the ERK1/2 pathway through
phosphorylation and inactivation of
its upstream activators. Interestingly, epidermal growth
factor-mediated stimulation of Akt is also higher in RSK2-deficient
cells (43), suggesting
that Akt may compensate for the loss of RSK2 or that RSK2 is also
involved in feedback inhibition of the phosphatidylinositol
3-kinase/Akt pathway through an unknownmechanism.
MSK Subfamily
Discovery.
Mitogen- and
stress-activated kinases 1 and 2 (MSK1 and MSK2)
were both identified
in 1998 through genomewide homology searches
(
38,
137)
and as a result of
a two-hybrid screen with p38

as the bait
(
149).
Human MSK1
(RSK-like protein kinase, or RLPK) and MSK2 (RSK-B)
are 75%
identical and, like the RSK enzymes, have two distinct
kinase domains
(Fig.
3). Although the
MSKs have relatively high
levels of homology to the RSKs (40%
identity), they are thought
to form a subfamily of MKs activated by
both mitogens and stress
stimuli (Fig.
6). MSK homologues have
also been identified in
different species. While no homologues have
been found in
S. cerevisiae to date, the
C. elegans
hypothetical protein kinase
C54G4 and the
D. melanogaster
kinase JIL-1 are homologous to
human MSK1, with 50 and 45% amino
acid identity, respectively
(
89).
Although the role
of C54G4 is unknown, JIL-1 mediates histone
H3
phosphorylation in
D.
melanogaster (
89),
which appears to
be an evolutionarily conserved function for MSK1 and
-2 (
190).
Similar to the
RSKs, the NTKD of MSK1 and -2 belongs to the
AGC family of kinases and
is most similar to S6K1 and S6K2 (40%
amino acid identity). The
CTKD of MSK1 and -2 has a CaMK-like
sequence and is mostly homologous
to the kinase domain of MK2
and -3 (about 40% amino acid
identity) (Fig.
4).
Structure and expression.
MSK1 and MSK2 share the
major structural characteristics of the RSKs, including two distinct
catalytic domains, a linker region of about 100 amino acids, and
relatively similar C- and N-terminal regions (Fig.
3). Analogous to the RSKs,
the NTKD of MSK1 and -2 is considered to be mainly responsible for
substrate phosphorylation, and the
CTKD is involved in MSK1 and -2 activation through
autophosphorylation of the
kinase. Both MSK isoforms contain a D domain (Leu-Ala-Lys-Arg-Arg-Lys)
in their C terminus that lies within a region found to be necessary for
MSK2 docking to ERK1/2 and p38 (Fig.
2)
(207).
Unlike the
RSKs, MSK1 and -2 are usually present in the nuclei of quiescent cells
(38,
149,
207). The C-terminal
region of the MSKs contains a functional bipartite NLS
(Lys-Arg-Xaa14-Lys-Arg-Arg-Lys-Gln-Lys in MSK2) (Fig.
2) which confers on MSK1
and MSK2 an almost exclusive nuclear localization
(38,
149). Although it is
unknown whether the MSKs translocate to different cellular locations
following activation, expression of MSK2 was found to regulate the
location of ectopically expressed p38
and ERK1
(149). For instance, in
the absence of MSK2, both p38
and ERK1 localized to the
nucleus and cytoplasm, but upon expression of MSK2 constructs
containing an intact D domain, p38
and ERK1 shifted to a more
nuclear localization
(149). These results
indicate that MSK1 and MSK2 may control the cellular localization of
their upstream activators, ERK1/2 and p38, a finding that was also
observed with the closely related kinase MK2
(6).
Analysis of
MSK1 and MSK2 expression in different tissues revealed that they are
ubiquitously expressed, with predominant expression of the
msk1 and msk2 mRNAs in the brain, heart,
placenta, and skeletal muscles
(38). Interestingly, the
msk2 gene maps to the BBS1 locus on chromosome 11
(248). Bardet-Beidl
syndrome (BBS) is a genetically heterogeneous disorder characterized
primarily by retinal dystrophy, obesity, polydactyly, renal
malformations, and learning disabilities
(92). Although MSK2
inactivation has not yet been shown to contribute to Bardet-Beidl
syndrome, it is worth noting that the clinical symptoms are reminiscent
of Coffin-Lowry syndrome, suggesting that inactivation of RSK2 and MSK2
may contribute to similar
disorders.
Activation mechanisms.
MSK1 and MSK2 are potently
activated in vivo by ERK1/2 and p38 but not JNK
(38,
149), indicating that
both mitogens and stress stimuli lead to the activation of MSK1 and -2.
Indeed, specific inhibitors of p38
and p38ß (SB203580)
and MEK1 and -2 (U0126) block MSK1 and -2 activation, depending on the
origin of the stimuli (Fig.
6). Although the
site-specific and sequential
phosphorylation events during MSK1
and -2 activation have not yet been fully characterized, the four key
phosphorylation sites present in
RSKs are conserved in MSK1 and -2 (Fig.
7), suggesting that they
have similar activation mechanisms
(56). Indeed, changing
all four residues to Ala inactivates MSK2 in response to MEK1 and MEK6
activation (208). Two of
the four essential sites in MSK1 and -2 (Ser360 within the turn motif
and Thr581 in the CTKD activation loop of MSK1) are followed by a
proline residue, suggesting that they are likely ERK1/2 and p38
phosphorylation sites (Fig.
7). The two other
phosphorylation sites are
homologous to most AGC kinases and lie within the hydrophobic motif
(Ser376) and the NTKD activation loop (Ser212) of MSK1. Inactivation of
either kinase domain through mutation of conserved residues completely
blocks the N-terminal kinase activity of MSK1 and -2
(38,
149,
208). Similar mutations
in the CTKD of RSK1 and RSK2 have been shown to only partly reduce the
activity of RSK1 and RSK2 against exogenous substrates
(10,
29,
165), indicating that,
unlike the RSKs, MSK1 and -2 activation critically requires CTKD
activation (29). Since
RSK1 translocates to the plasma membrane for full activation
(159), the different
requirements of these kinases for CTKD activity could be explained by
their different cellular localizations.
During activation of the
RSKs, phosphorylation of the
hydrophobic motif creates a docking site for PDK1, allowing it to
phosphorylate the activation loop of the NTKD. These
phosphorylation sites are also
conserved within MSK1 and MSK2 (Fig.
7), implying similar
activation mechanisms. However, recent data indicate that MSK1 becomes
fully activated in PDK1-null embryonic stem cells
(229), suggesting that a
kinase other than PDK1 phosphorylates the activation loop of MSK1 and
-2. The high homology between the activation loop sequences of the RSKs
and MSKs suggests that the kinase responsible for the
phosphorylation of this site may be
similar or related to PDK1. Although it is possible that the MSKs
regulate their own activation loop through
autophosphorylation, it
seems more likely that an unknown PDK1-like kinase phosphorylates this
site in vivo. Analogous to the RSKs, the MSKs have a phosphate-binding
pocket within the NTKD that mediates intramolecular interaction with
the phosphorylated hydrophobic
motif (34,
55). This pocket was
shown to be essential for MSK1 kinase activation, which underscores the
importance of hydrophobic motif
phosphorylation in MSK1 and -2
activation. It is clear that further experiments will be necessary to
characterize the regulation of the hydrophobic motif in MSK1 and -2 and
to identify the kinase responsible for the
phosphorylation of this
site.
According to their homology to the RSKs, the MSKs may also
contain two additional
phosphorylation sites. Based on
work from our group
(165), the role of the
site located near the C terminus of MSK2 (Ser737) may be to regulate
its association with ERK1/2 and p38. Although the D domain of MSK1 and
-2 is located near the C terminus, MSK1 and MSK2 have an additional 20
and 50 amino acids C-terminal to the docking site, respectively,
suggesting that these regions may contain additional elements necessary
for ERK1/2 and p38 association (Fig.
7).
Substrates and functions.
The substrate specificity
of the MSKs resembles that of the RSKs, with the minimal consensus
substrate sequence Arg-Xaa-Xaa-pSer/Thr
(38), indicating that the
MSKs and RSKs may have similar targets. MSK1 and MSK2 are localized in
the nucleus of quiescent and activated cells
(38,
149), which suggests
that they may preferentially phosphorylate nuclear substrates.
Consistent with this, studies from newly engineered MSK1-, MSK2-, and
MSK1/MSK2-deficient mice indicated that MSK1 and -2 play active roles
in transcriptional regulation and in the nuclear response to stress and
mitogens (2,
176,
228) (Fig.
8).
(i) Transcriptional regulation by MSK.
Upon
activation, MSK1 and -2 are capable of phosphorylating multiple
transcription factors and nuclear proteins, thereby increasing their
stability or activity. As mentioned for the RSKs, the transactivation
potential of the related transcription factors CREB and ATF1 depends on
phosphorylation of a Ser residue in
the kinase-inducible domain (Ser133 and Ser63 for CREB and ATF1,
respectively). Both sites are
phosphorylated in response to
growth factors and cellular stresses, via the ERK1/2 and p38
pathways, respectively. Upon their discovery, MSK1 and MSK2 were shown
to phosphorylate CREB on Ser133 in vitro with a Km
much lower than that of the protein kinases RSK1 and MK2
(38,
149), raising the
possibility that MSK1 rather than RSK1 mediates the mitogen-stimulated
phosphorylation of CREB. Since
then, work by several groups has supported the involvement of MSK1 and
-2 in CREB phosphorylation with
different pathway inhibitors
(72,
107).
Further
supporting the role of MSK1 and -2 as the mitogen- and
stress-induced kinases responsible for CREB
phosphorylation, knockout mice for
MSK1, MSK2, and both kinases have recently been engineered
(2,
176,
228). Stress-induced
phosphorylation of CREB and ATF1
was found to be completely impaired in primary embryonic fibroblasts
derived from MSK1/MSK2 knockout animals
(228). Importantly,
mitogen-induced phosphorylation of
CREB and ATF1 was partially inhibited in these cells, suggesting that
the RSKs may also contribute to the mitogenic response leading to CREB
and ATF1 phosphorylation. As
mentioned above, CREB activation participates in the transcriptional
activation of several immediate-early genes, such as c-fos,
junB, and egr1
(116). The knockout of
both MSK1 and MSK2 resulted in a 50% reduction in c-fos
and junB transcription in response to stress but only a
minimal reduction in response to mitogenic stimulation
(228), suggesting again
that MSK1 and -2 regulate the immediate-early genes in response to
stress stimuli.
Similar to RSK1, MSK1 has been shown to mediate
NF-
B-dependent transcription through
phosphorylation of the
NF-
B isoform p65 on Ser276
(216). Loss of MSK1 and
-2 in mouse fibroblasts resulted in reduced tumor necrosis
factor-mediated activation of NF-
B, suggesting that
stress-stimulated activation of MSK1 and -2 is important for the
activation of NF-
B-dependent transcription
(216). MSK1 has also
been shown to phosphorylate the transcription factors ER81
(86) and STAT3
(227,
244); however, the use
of MSK1/MSK2-null mouse fibroblasts will be necessary to elucidate the
role of MSK1 and -2 in stress- and mitogen-mediated activation of ER81
and STAT3 because other MKs have also been shown to phosphorylate these
factors.
(ii) MSK mediates the nucleosomal response.
The nucleosomal
response refers to the rapid
phosphorylation of histone H3 on
Ser10 and HMG-14 on Ser6 that occurs concomitantly with
immediate-early gene induction in response to a wide variety of stimuli
(204). The fact that the
ERK1/2- and p38-mediated signaling pathways culminate in a common
nucleosomal response suggests that there may be a common nuclear
effector. Although RSK1 and RSK2 have been shown to phosphorylate
histone H3 in vitro and in vivo
(168,
173), the MSKs were
recently shown to be the prominent kinases involved in the nucleosomal
response of somatic cells
(190). Indeed, stress-
and mitogen-induced phosphorylation
of histone H3 and HMG-14 was found to be completely inhibited in
primary embryonic fibroblasts from MSK1/MSK2 knockout animals
(190), ruling out the
possible involvement of other kinases such as the RSKs
(37).
(iii) Other targets of MSK.
The MSKs have been
shown to phosphorylate many more targets involved in diverse
cellular processes. MSK1 and/or MSK2 has recently been shown to
phosphorylate Bad (182),
Akt (140), and 4E-BP1
(114) in response to UV
irradiation, but the biological role of MSK1 and -2 in these processes
remains to be determined.
MNK Subfamily
Discovery.
MAPK-interacting kinases 1 and 2 (MNK1 and
-2) form a subfamily
of MKs that were discovered in 1997 as a result of
a two-hybrid
screen designed to identify ERK2 binding proteins
(
221) and
in a novel
phosphorylation screen looking for
ERK1 substrates
(
60).
Human MNK1 has approximately 70% amino acid identity with
MNK2,
which differs from MNK1 mostly within its C-terminal region
(Fig.
3 and
4). Homologues of the MNKs
have been identified
in other species. MNK1 displays relatively high
homology (51%
amino acid identity) to a large protein kinase in
D. melanogaster termed LK6, which was found to localize to
centrosomes and to
regulate microtubule organization
(
93). MNK1 also has
homology
(46% amino acid identity) to the hypothetical protein
kinase
R166.5 found in
C. elegans, but as with many MKs, no
homologues
of MNK1 and MNK2 have been identified in
S.
cerevisiae. The
MNK1 and -2 catalytic domain belongs to the CaMK
family of kinases
and is most similar to the CTKD of the RSKs
(33% amino acid
identity) and MK2 and -3
(
221) (Fig.
4).
Structure and expression.
While the mnk1
gene encodes only one isoform of 424 amino acids, transcription of the
mnk2 gene generates two spliced isoforms, referred to as MNK2A
and MNK2B, which are 465 and 414 amino acids in length, respectively
(Fig. 3)
(187). MNK2B lacks the
C-terminal 52 amino acid containing the D domain (Fig.
4) and has been shown to
be a poor substrate for ERK1/2 and p38 in vitro
(170). The D domain of
MNK1 consists of Leu-Ala-Arg-Arg-Arg (Fig.
2) and mediates the
interaction of MNK1 with both ERK1/2 and p38
(60,
221). The D domain
present in MNK2A contains only two contiguous basic residues
(Leu-Ala-Gln-Arg-Arg), which is subtly different from the D
domain in MNK1 (Fig.
2). This domain is highly
reminiscent of the D domain found in RSKs, and consistent with this,
MNK2A has been shown to interact only with ERK1/2
(221). The regulation of
ERK1/2 and p38 interaction with the MNKs is currently unknown, but MNK1
has been shown to selectively bind
unphosphorylated inactive
ERK2 (221), suggesting
that the complex between the two kinases may be regulated in a
phosphorylation-dependent manner,
similar to regulation by the RSKs
(165).
While MNK1
and MNK2A localize primarily to the cytoplasm, MNK2B is enriched in the
nucleus of quiescent cells. All three proteins contain a polybasic
sequence in their N terminus that functions as a potent NLS
(170). With a two-hybrid
strategy, the NLS of MNK1 has been shown to mediate binding to
importin-
, which is an intracellular receptor protein that
mediates nuclear import
(146,
222). The cytoplasmic
localization of MNK1 can be explained by the presence of a CRM1-type
nuclear export signal (NES) in its C terminus
(Leu-Ala-Asp-Gly-Leu-Cys-Ser-Met-Lys-Leu)
(146). The NES of MNK1
is functional, because leptomycin B (which blocks CRM1-dependent
nuclear export) was shown to trap MNK1 in the nucleus, revealing that
MNK1 is actively shuttling between the cytoplasm and the nucleus
(121,
146). The C terminus of
MNK2B does not contain such a motif, which correlates with its mostly
nuclear localization. Because MNK2A lacks critical residues important
for NES function, its cytoplasmic localization has been more of a
mystery, but recent data suggest that its nuclear export is regulated
by the intramolecular interaction between its N and C termini, which
masks and unmasks critical regions necessary for nuclear export
(170).
MNK1 and
MNK2 are expressed in all adult tissues with the exception of the
brain, where levels are greatly reduced
(221). The expression of
both proteins is especially abundant in skeletal
muscles.
Activation mechanisms.
Although ERK1/2 and p38 are both capable of
phosphorylating MNK1, MNK2A, and, to a lesser extent, MNK2B in vitro,
MNK1 is the only isoform that can be activated by the p38 pathway in
vivo (221) (Fig.
9). MNK1 has low basal activity in cells and is responsive to both stress-
and mitogen-stimulated pathways
(60,
221). MNK2A and, to a
lesser extent, MNK2B appear to have high basal activity compared to
MNK1 in quiescent cells
(170), but the role
of MNK2A and MNK2B in resting cells is unknown. Despite the
fact that MNK2A possesses a potential ERK docking domain, both MNK2
isoforms are only marginally regulated by mitogen stimulation
(170), indicating that
further investigation will be necessary to uncover the specific roles
of the MNKs in quiescent and stimulated cells.
Phosphopeptide
analysis of MNK1 and MNK2 revealed the presence
of several
MAPK-stimulated
phosphorylation sites
(
169,
222).
Two of these
proline-directed sites (Thr255 and Thr385 in the
activation loop in
MNK1) are homologous to residues in MK2 and
-3 that have been shown to
be phosphorylated by p38 and
necessary
for MK2 activity
(
7), suggesting similar
activation mechanisms
(Fig.
3). Substitution of both
sites with Ala residues in MNK1
and -2 results in inactive kinases
(
170,
221,
222), and phosphomimetic
mutation
of Thr385 was found to activate MNK1
(
60), indicating the
importance
of these sites in MNK1 and -2 activation. Deletion of the
C-terminal
91 amino acids containing the D domain was also shown to
render
MNK1 inactive
(
60), suggesting that
ERK1/2 and/or p38 docking
and
phosphorylation of two important
regulatory sites are required
for efficient MNK1 and MNK2
activation.
Substrates and functions.
Regulation of protein synthesis
by the eukaryotic initiation factor 4F (eIF4F) complex plays an
important role in controlling cell growth and proliferation (reviewed
in reference 191). In
higher eukaryotes, the eIF4F complex consists of three subunits, eIF4A,
eIF4E, and eIF4G. eIF4E recruits mRNAs to the complex through
binding of their 5' cap structure, the
N7-methylguanosine cap. eIF4E also interacts with
the scaffold protein eIF4G, which recruits the RNA helicase eIF4A to
the complex, unwinds the secondary structure in the mRNA, and
facilitates translation initiation by the 40S ribosomal complex. The
activity of eIF4E is considered to be partly regulated by
phosphorylation at Ser209, and
mitogens and stresses have been shown to induce eIF4E
phosphorylation through ERK1/2 and
p38 (53).
MNK1 was
found to be recruited to the eIF4F complex through its association with
the C terminus of eIF4G
(155), making it a
likely candidate kinase that mediates eIF4E
phosphorylation (Fig.
8). Consistent with this
idea, MNK1 and MNK2 were later found to phosphorylate eIF4E at Ser209
in response to stress and mitogen stimulation
(95,
169,
221). MNK1 can also
phosphorylate eIF4G and bind to phosphoprotein p97 in vitro, but
whether these events also occur in vivo remains to be determined
(154). The biological
significance of eIF4E
phosphorylation is not completely
understood. Through an unknown mechanism,
phosphorylated eIF4E was reported
to interact more efficiently with eIF4G
(16), and
phosphorylation of eIF4E has been
shown to both increase
(126) and diminish
(172) its affinity for
the cap structure of the mRNA. Recent findings show that MNK1-
and MNK2-mediated phosphorylation
of eIF4E on Ser209 correlates with reduced cap-dependent translation
(95). Thus, it seems
clear that future work aimed at analyzing the role of the MNKs in
translation control, for example, through the generation of MNK1 and -2
knockout mice and fibroblasts, will likely help to clarify the function
of eIF4E phosphorylation
(171).
MNK2B but
not MNK1 or MNK2A binds to estrogen receptor ß
(187), which is highly
reminiscent of the phosphorylation
of estrogen receptor
by RSK1
(90). Addition of the
steroid estradiol increased the interaction between MNK2B and estrogen
receptor ß, but whether MNK2B phosphorylates estrogen receptor
ß to affect its function remains
unknown.
MK2 and -3 Subfamily
Discovery.
MK2 was discovered in 1992 by Philip Cohen and
colleagues as
a protein kinase activated by ERK1/2 from rabbit skeletal
muscle
(
192). MK3 was
later discovered by a two-hybrid screen looking
for interactors of p38
(
122) and as the product
of a gene commonly
deleted in small-cell lung cancer cells (Table
1)
(
186). MK2
homologues
have been identified in
D. melanogaster and
C.
elegans,
which show about 60% amino acid identity with
human MK2 (
106).
Interestingly,
the yeast protein kinases Rck1 and Rck2 show some
homology with
MK2 (about 35% amino acid identity) and represent
the sole MK-related
kinases identified to date in the
S.
cerevisiae genome
(
157).
Rck1 and Rck2
have been shown to play roles in the inhibition
of meiosis in
S.
cerevisiae, but no such functions have yet
been attributed to MK2.
MK2 is highly homologous to MK3 (75%
amino acid identity), which
suggests that they form a subfamily
of related kinases (Fig.
5). The kinase domains of
MK2 and -3
are most similar (35 to 40% identity) to CaMK,
phosphorylase
b kinase, and the CTKD of the RSK isoforms
(
193,
249) (Fig.
4).
Structure and expression.
While the mk2
gene encodes two alternatively spliced transcripts of 370 amino acids
(MK2A) and 400 amino acids (MK2B)
(27,
192), the mk3
gene encodes only one transcript of 382 amino acids
(186). These proteins
are highly homologous, yet MK2A possesses a shorter C-terminal region.
The C terminus of MK2B contains a functional bipartite NLS
(Lys-Lys-Xaa10-Lys-Arg-Arg-Lys-Lys) that is not present in
the shorter MK2A isoform (Fig.
3), indicating that
alternative splicing determines the cellular localization of the MK2
isoforms. MK3 possesses a similar NLS, but the functionality of this
domain has not yet been tested by mutational analysis. The NLS found in
both MK2B and MK3 also encompasses a D domain
(Leu-Leu-Lys-Arg-Arg-Lys-Lys in MK2B) (Fig.
2) that was shown to
mediate the specific interaction of MK2B and MK3 with p38
and
p38ß (188). MK2B
and MK3 also possess a functional NES located N-terminal to the NLS and
D domain (Fig. 3). The NES
in MK2B is sufficient to trigger nuclear export following stimulation,
which can be inhibited by leptomycin B
(6,
44). The sequence
N-terminal to the catalytic domain in MK2 and MK3 is proline rich and
contains one (MK3) or two (MK2) putative Src homology 3 (SH3)
domain-binding sites, which have been shown, for MK2, to mediate
binding to the SH3 domain of c-Abl in vitro
(45,
151). Recent data
suggest that this domain is involved in MK2-mediated cell migration
(102).
While MK2A
is mostly present in the cytoplasm, MK2B and MK3 are predominantly
located in the nucleus of quiescent cells
(44,
134). Upon stress
stimulation, both MK2B and MK3 are rapidly exported to the cytoplasm
via a CRM1-dependent mechanism
(6,
44,
179). Nuclear export of
MK2B appears to be mediated by kinase activation, as phosphomimetic
mutation of Thr334 within the activation loop of the kinase enhances
the cytoplasmic localization of MK2B
(44). For this reason, it
is thought that MK2B and MK3 contain a constitutively active NLS and a
phosphorylation-regulated
NES.
MK2 and MK3 appear to be ubiquitously expressed, with
predominant expression in the heart, skeletal muscle, and kidney
tissues (186,
192).
Activation mechanisms.
ERK1/2 and p38 were first
reported to activate MK2 and MK3 in vitro
(7,
46,
83,
117), but it was later
found that ERK1 and -2 are not physiological MK2 and -3 kinases. Thus,
MK2 and MK3 activity is potently stimulated by various activators of
p38
and p38ß
(54,
70,
122,
163) (Fig.
10).
p38 was found to mediate the in vitro and in vivo
phosphorylation
of MK2 on four
proline-directed sites, Thr25, Thr222, Ser272,
and Thr334
(
7), of which only Thr25
is not conserved in MK3.
The function of
phosphorylated Thr25 is unknown,
but its location
between the two SH3 domain-binding sites suggests that
it may
regulate protein-protein interactions. Thr222 in MK2 (Thr201
in
MK3) is located in the activation loop of the kinase domain
and has
been shown to be essential for MK2 and MK3 kinase activity
(
7,
46,
117).
Thr334 in MK2
(Thr313 in MK3) is located C-terminal to the catalytic
domain and is
essential for kinase activity
(
117,
192). The
crystal
structure of MK2 has been resolved and suggests that
Thr334
phosphorylation may serve as a
switch for MK2 nuclear
import and export
(
124). It is also
thought that phosphorylation
of
Thr334 would weaken or interrupt binding of the C terminus
of MK2 to
the catalytic domain, exposing the NES and promoting
nuclear export.
Such conformational changes in MK2 are also
supported by a
FRET analysis of a green fluorescence protein
(GFP)-MK2
fusion protein, which revealed that activation of
MK2 is accompanied by
an open conformation of the protein which
only becomes detectable in
the cytoplasm of activated cells
(
133).
While p38
is capable of activating MK2 and MK3 in the nucleus, the cellular
location of p38 itself has been shown to be controlled by MK2 and
possibly MK3. Following
phosphorylation and activation of
MK2, nuclear p38 has been shown to be exported to the cytoplasm in a
complex with MK2 (6). The
interaction between p38 and MK2 also appears to be important for p38
stabilization, because a recent report indicated that p38 levels are
low in MK2-deficient cells and expression of a catalytically inactive
MK2 protein restores p38 levels
(102). These results
suggest that activation and nuclear export of MK2 and -3 are coupled by
a phosphorylation-dependent
conformational switch that also dictates p38 stabilization and
localization.
Substrates and functions.
MK2 shares many substrates with
MK3 (Fig. 8); the two
enzymes have comparable substrate preferences and phosphorylate peptide
substrates with similar kinetic constants
(32). The minimum
sequence required for efficient
phosphorylation by MK2 was found to
be Hyd-Xaa-Arg-Xaa-Xaa-pSer/Thr, where Hyd is a bulky hydrophobic
residue
(193).
Experimental
evidence supports a role for p38 in the regulation of cytokine
biosynthesis (73,
108) and cell migration
(76,
150). The targeted
deletion of the mk2 gene in mice provided the unexpected
result that, although p38 mediates the activation of many similar
kinases, MK2 seems to be the key kinase responsible for these
p38-dependent biological processes
(101,
102). Loss of MK2 leads
to a defect in lipopolysaccharide-induced synthesis of cytokines such
as tumor necrosis factor alpha, interleukin-6, and gamma interferon
(101) and also to
changes in the migration of mouse embryonic fibroblasts, smooth muscle
cells, and neutrophils
(75,
102,
132). Consistent with a
role for MK2 in inflammatory responses, MK2-deficient mice show
increased susceptibility to Listeria monocytogenes infection
(109) and reduced
inflammation-mediated neuronal death following focal ischemia
(218). Since the levels
of p38 protein are also significantly reduced in MK2-deficient cells,
it was necessary to distinguish whether these phenotypes were due
solely to the loss of MK2
(100). To achieve this,
MK2 mutants were expressed in MK2-deficient cells, and the results
indicated that the catalytic activity of MK2 was not necessary to
restore p38 levels but was required to regulate cytokine
biosynthesis
(102).
(i) Regulation of mRNA translation.
MK2 was shown to increase tumor necrosis factor
alpha production by increasing the rate of translation of its
mRNA (101,
132). Indeed, no
significant reductions in the transcription, processing, and shedding
of tumor necrosis factor alpha could be detected in MK2-deficient mice
(101,
132). The p38 pathway is
known to play an important role in regulating mRNA stability
(99,
215), and MK2 represents
a likely target of p38 mediating of this function
(231). Recent data
obtained from MK2-deficient mice indicated that the catalytic activity
of MK2 is necessary for its effects on cytokine production and
migration (102),
suggesting that MK2 phosphorylates targets involved in mRNA
stability. Consistent with this, MK2 has been shown to bind and/or
phosphorylate the heterogeneous nuclear ribonucleoprotein (hnRNP) A0
(164), tristetraprolin
(119), the
poly(A)-binding protein PABP1
(11), and HuR
(74,
209). These substrates
are known to bind or copurify with mRNAs that contain AU-rich
elements in the 3' untranslated region
(69), suggesting that MK2
may regulate the stability of AU-rich mRNAs such as tumor
necrosis factor alpha. It is currently unknown whether MK3 plays
similar functions, but lipopolysaccharide treatment of MK2-deficient
fibroblasts completely abolished hnRNP A0
phosphorylation, suggesting that
MK3 is not able to compensate for the loss of MK2
(164).
MK3
participates with MK2 in
phosphorylation of the eukaryotic
elongation factor 2 (eEF2) kinase, the enzyme that phosphorylates and
inactivates eEF2 (96).
eEF2 activity is critical for the elongation of mRNA during
translation, and phosphorylation of
eEF2 on Thr56 results in the termination of mRNA translation.
MK2 and -3 phosphorylation of eEF2
kinase on Ser377 suggests that these enzymes can modulate eEF2 kinase
activity and thereby regulate mRNA translation elongation
(96).
(ii) Transcriptional regulation by MK2 and -3.
Similar to many MKs, nuclear MK2 contributes to the
phosphorylation of CREB
(199), serum response
factor (77), and ER81
(85). Comparison of
wild-type and MK2-deficient cells revealed that MK2 is the major SRF
kinase induced by stress
(77), suggesting a role
for MK2 in the stress-mediated immediate-early response. Both MK2 and
MK3 interact with basic helix-loop-helix transcription factor E47 in
vivo and phosphorylate E47 in vitro
(134). MK2-mediated
phosphorylation of E47 was found to
repress the transcriptional activity of E47 and thereby inhibit
E47-dependent gene expression, suggesting that MK2 and -3 may regulate
tissue-specific gene expression and cell differentiation
(134).
(iii) Other targets of MK2 and -3.
Several other
MK2 and -3 substrates have also been identified, suggesting that MK2
and -3 play diverse functions in several biological processes. With a
functional proteomic approach consisting of mass spectrometric
phosphoprotein identification following in vitro
phosphorylation of neutrophil
lysate by active recombinant MK2, the scaffolding protein
14-3-3
was identified as a physiological MK2 substrate
(153). 14-3-3
was reported to interact with a number of components of cell signaling
pathways, including protein kinases, phosphatases, and transcription
factors (reviewed in reference
214). MK2-mediated
phosphorylation of 14-3-3
on Ser58 was shown to compromise its binding activity
(153), suggesting that
MK2 may affect the regulation of several signaling molecules normally
regulated by 14-3-3
.
With the same approach, MK2 was
found to also interact with and to phosphorylate the p16 subunit of the
seven-member Arp2 and -3 complex, p16-Arc, on Ser77
(185). p16-Arc plays
roles in regulating the actin cytoskeleton, suggesting that MK2 may be
involved in this process. Consistent with such a role for MK2, the
small heat shock protein HSP27
(54,
163,
194),
lymphocyte-specific protein LSP-1
(80), and vimentin
(26) have been shown to
be phosphorylated by MK2. HSP27 is
of particular interest because it forms large oligomers which can act
as molecular chaperones and protect cells from heat shock and oxidative
stress (105). Upon
phosphorylation, HSP27 loses its
ability to form large oligomers and is unable to block actin
polymerization (105,
162), suggesting that
MK2-mediated phosphorylation of
HSP27 serves a homeostatic function aimed at regulating actin dynamics
that would otherwise be destabilized during stress
(51,
70). Interestingly, MK3
was also shown to phosphorylate HSP27 in vitro and in vivo
(117,
122), but its role
during stressful conditions has not yet been addressed.
MK2 and
MK3 can also phosphorylate 5-lipoxygenase, an enzyme that catalyzes the
initial steps in the formation of the inflammatory mediators
leukotrienes (224).
Tyrosine hydroxylase
(195), glycogen synthase
(192), and Akt
(158) were also shown to
be phosphorylated by MK2. Finally,
MK2 phosphorylates the tumor suppressor protein tuberin on Ser1210,
creating a docking site for 14-3-3
(113). Tuberin and
hamartin normally form a functional complex that negatively regulates
cell growth by antagonizing mTOR-dependent signaling
(203), suggesting that
p38-mediated activation of MK2 may regulate cell growth by increasing
14-3-3 binding to
tuberin.
MK5
Discovery.
MK5
(p38-regulated/activated protein kinase) was discovered
through
homology searches of expressed sequence tag database
with the MK2
sequence as the query
(
136,
139). MK5 has 40%
amino
acid identity with MK2 and MK3, which suggests that it is a
more
distant homologue of these proteins (Fig.
5). Indeed, MK5
may have
originated earlier during evolution from a common ancestral
protein,
because MK2 and -3 and MK5 have roughly the same amino
acid
relatedness to the MK2 homologues found in
D. melanogaster and
C. elegans. Like MK2 and MK3, the kinase domain of MK5 is
most
similar to that of CaMK-related kinases (Fig.
3). Because
MK5 is a
relatively new MK family member, less is known about
its activation
mechanism and function.
Structure and expression.
The mk5 gene encodes
two alternatively spliced transcripts of 471 amino acids (MK5A) and 473
amino acids (MK5B), but the relevance of having two nearly identical
isoforms is unknown (Fig.
5). MK5A and MK5B are
similar in structure to MK2 and -3, possessing a kinase domain bordered
with a short N-terminal region lacking the SH3 domain binding motif and
a C-terminal region that contains a functional NLS, NES, and D domain
(Fig. 3). The NLS
(Arg-Lys-Arg-Lys) of MK5 was shown to be functional because alanine
substitutions were found to disrupt the nuclear localization of MK5
(179). The NLS also
overlaps a D domain (Ile-Leu-Arg-Lys-Arg-Lys-Leu-Leu) that mediates
interaction with p38
and p38ß
(179). Interaction of
p38 with MK5 was found to be weaker than with MK2, and consistent with
this, MK5 does not appear to stabilize p38 in vivo
(183). The NES of MK5
(Leu-Arg-Val-Ser-Leu-Arg-Pro-Leu-His-Ser) is functional and is
sufficient to trigger CRM1-dependent nuclear export, as shown by
leptomycin B experiments
(179).
When
overexpressed, MK5 localizes to the nucleus of quiescent cells, but
upon cellular stress, MK5 translocates to the cytoplasm
(135,
179). Interestingly,
expression of exogenous p38
with MK5 has been shown to
relocate MK5 to the cytoplasm, suggesting that p38 docking interferes
with the function of its NLS
(179). MK5 expression
appears to be ubiquitous, with predominant expression in the heart and
skeletal muscle (136,
139).
Activation mechanisms.
Upon its discovery, MK5 was
found to be activated by p38
and p38ß through
phosphorylation of Thr182, located
in the activation loop of the kinase domain
(135,
136,
179) (Fig.
4). However, recent data
have challenged these results, because MK5 activity does not appear to
be significantly increased by stimulation of the p38 cascade
(183) (Fig.
10). While MK2 was able
to interact with p38 and become activated by extracellular stresses,
endogenous MK5 did not display the same properties
(183), indicating that
more experimentation will be necessary to fully characterize MK5's
activation mechanisms and functions. In addition, the generation of
MK5-specific reagents will be necessary to distinguish MK5- from MK2
and -3-dependent functions.
Substrates and functions.
MK5 has originally been
shown to share many substrates with MK2, such as HSP27 and glycogen
synthase (136), but the
recent description of mice rendered null for MK5 by homologous
recombination has suggested the need for a reevaluation of these
results (183) (Fig.
8). Despite the relatively
high similarity between MK2 and MK5 (Fig.
4), MK5-deficient mice did
not display any of the phenotypic changes seen in MK2-deficient animals
(101). Although no MK5
protein or kinase activity was detected in the MK5 knockout mice, the
animals were viable and fertile and did not display abnormalities in
tissue morphology or behavior
(183). The parallel
analysis of MK5- and MK2-deficient fibroblasts revealed that MK2 but
not MK5 is able to phosphorylate HSP27 at the physiological residue in
vivo (183). Indeed, the
loss of MK5 expression did not affect HSP27
phosphorylation induced by stress
stimulation, indicating that MK2 is the sole regulator of
stress-stimulated HSP27
phosphorylation in vivo
(183). The authors also
found that the MK5 antibody originally used to demonstrate the ability
of MK5 to phosphorylate HSP27 actually cross-reacts with MK2 and MK3
(136), explaining the
discrepancies between different reports
(183). Because of the
high homology between MK2 and MK5, future substrates of MK5 should be
tested in MK5-deficient cells to determine whether they are also shared
with MK2.

CONCLUSIONS AND PERSPECTIVES
Recent evidence indicates that, although they have
relatively
high homologies and are activated by similar mechanisms,
each
MK family member will exert specific functions within a cell.
Currently
available data suggest that ERK- and p38-responsive MKs
generally
function during mitogenic and stressful conditions,
respectively.
For example, one might predict that active p38 will
stimulate
MK2 and -3 activity, which in turn will regulate actin
reorganization
and mRNA stability in response to various
physical and chemical
stresses. MK2 is also responsible for increasing
the mRNA stability
of several cytokines that are required in
response to viral
or bacterial insults that activate the p38 signaling
cascade.
Another example involves ERK1/2-mediated activation of the
RSKs,
which are usually thought of as having roles in cell survival
and
proliferation in response to mitogenic signaling.
Activation of
the RSKs during mitogenic conditions seems logical, but it is more
difficult to understand the need for a cell to have kinases that
respond to both mitogenic and stress stimuli. While the RSKs and MK2
and -3 are activated solely by ERK1/2 and p38, respectively, the MSKs
and MNKs are functionally positioned to integrate these two signaling
pathways, indicating that cellular stresses and mitogens induce
specific and overlapping responses. One can imagine that the MSK1- and
-2-mediated regulation of histone H3 and HMG-14 is necessary
to allow either ERK1/2- or p38-mediated effectors to stimulate
transcription. In the same vein, activation of the MNKs would result in
increased mRNA translation, which may be necessary for both
the ERK1/2 and p38 signaling cascades to exert their functions. Does
this mean that MSK1 and -2 and MNK1 and -2 have more diverse and
important functions because these kinases are required in response to
both mitogens and stress stimuli? At present, this question cannot be
answered. Data from MK2, RSK2, and MSK1 and -2 knockout mice indicate
that MK2 knockout mice have a stronger phenotype than RSK2 knockout
mice, but interestingly, MSK1 and -2 knockout animals have a relatively
mild phenotype. Clearly, the generation of additional reagents that
inhibit specific members of the MK family will be necessary to answer
this question.
The diverse biological functions of the many ERK-
and p38-regulated MKs are generated by their unique structural
properties and temporal and spatial regulation. For example, the
differential cellular distribution of the RSKs and MSKs may dictate the
identity of their targeted substrates. Similarly, alternative splicing
of MK2A and MK2B appears to determine their localization by the
presence or absence of a functional NLS, and this will also likely
affect their regulation and the identity of the substrates targeted by
these enzymes. With regard to the structural aspects of signaling, the
RSKs have been shown to interact with several proteins. This property
is highly reminiscent of a scaffold protein and suggests that the RSKs
may be involved in creating specific signaling modules by bringing
together upstream activating kinases, adaptor proteins, and downstream
substrates.
The continual characterization of MK signaling
complexes and the identification of novel substrates should reveal
overlapping and unique biological functions for the various MKs. Along
these lines, a rewarding task for the future will be to generate
reagents to specifically inhibit the different MKs, allowing the
contribution of each kinase to various cellular responses to be
deciphered. Moreover, the generation of knockout mice for RSK1, RSK3
and RSK4, MNK1 and MNK2, and MK3, in addition to those already
generated, should lead to new information about their specific roles in
MAPK signaling. It is likely that we are just beginning to
understand the cellular processes regulated by the MKs, and future
studies should be most
enlightening.

ACKNOWLEDGMENTS
We thank
members of the Blenis laboratory for helpful discussions
and Rana
Anjum, Andrew Tee, and Leon Murphy for critical reading
of the
manuscript.
P.P.R. is supported by a fellowship from the
International Human Frontier Science Program
Organization.

FOOTNOTES
* Corresponding
author. Mailing address: Department of Cell Biology, Harvard Medical
School, 240 Longwood Ave., Boston, MA 02115. Phone: (617)
432-1281. Fax: (617) 432-1144. E-mail:
proux{at}hms.harvard.edu.


REFERENCES
- 1 Angenstein, F., W. T.
Greenough, and I. J. Weiler. 1998.
Metabotropic glutamate receptor-initiated translocation of protein
kinase p90rsk to polyribosomes: a possible factor regulating synaptic
protein synthesis. Proc. Natl. Acad. Sci. USA
95:15078-15083.[Abstract/Free Full Text]
- 2 Arthur,
J. S., and P. Cohen. 2000. MSK1 is required
for CREB phosphorylation in
response to mitogens in mouse embryonic stem cells. FEBS
Lett.
482:44-48.[CrossRef][Medline]
- 3 Ballif,
B. A., and J. Blenis. 2001. Molecular
mechanisms mediating mammalian mitogen-activated protein kinase
(MAPK) kinase (MEK)-MAPK cell survival signals.Cell Growth Differ.
12:397-408.[Free Full Text]
- 4 Behn-Krappa,
A., and A. C. Newton. 1999. The hydrophobic
phosphorylation motif of
conventional protein kinase C is regulated by
autophosphorylation.Curr. Biol.
9:728-737.[CrossRef][Medline]
- 5 Bellacosa,
A., T. O. Chan, N. N. Ahmed, K. Datta, S. Malstrom,
D. Stokoe, F. McCormick, J. Feng, and P. Tsichlis.1998
. Akt activation by growth factors is a multiple-step
process: the role of the PH domain. Oncogene
17:313-325.[CrossRef][Medline]
- 6 Ben-Levy,
R., S. Hooper, R. Wilson, H. F. Paterson, and C. J.
Marshall. 1998. Nuclear export of the stress-activated
protein kinase p38 mediated by its substrate MAPKAP kinase-2.Curr. Biol.
8:1049-1057.[CrossRef][Medline]
- 7 Ben-Levy,
R., I. A. Leighton, Y. N. Doza, P. Attwood, N.
Morrice, C. J. Marshall, and P. Cohen. 1995.
Identification of novel
phosphorylation sites required for
activation of MAPKAP kinase-2. EMBO J.
14:5920-5930.[Medline]
- 8 Bhatt,
R. R., and J. E. Ferrell, Jr.2000
. Cloning and characterization of Xenopus Rsk2, the
predominant p90 Rsk isozyme in oocytes and eggs. J.
Biol. Chem.
275:32983-32990.[Abstract/Free Full Text]
- 9 Bhatt,
R. R., and J. E. Ferrell, Jr.1999
. The protein kinase p90 rsk as an essential mediator
of cytostatic factor activity. Science
286:1362-1365.[Abstract/Free Full Text]
- 10 Bjorbaek,
C., Y. Zhao, and D. E. Moller. 1995.
Divergent functional roles for p90rsk kinase domains.J. Biol. Chem.
270:18848-18852.[Abstract/Free Full Text]
- 11 Bollig,
F., R. Winzen, M. Gaestel, S. Kostka, K. Resch, and H. Holtmann.2003
. Affinity purification of ARE-binding proteins
identifies polyA-binding protein 1 as a potential substrate in
MK2-induced mRNA stabilization. Biochem. Biophys. Res.
Commun.
301:665-670.[CrossRef][Medline]
- 12 Bonni,
A., A. Brunet, A. E. West, S. R. Datta,
M. A. Takasu, and M. E. Greenberg.1999
. Cell survival promoted by the Ras-MAPK
signaling pathway by transcription-dependent and -independent
mechanisms. Science
286:1358-1362.[Abstract/Free Full Text]
- 13 Bott,
C. M., S. G. Thorneycroft, and C. J.
Marshall. 1994. The sevenmaker gain-of-function
mutation in p42 MAP kinase leads to enhanced signalling and reduced
sensitivity to dual specificity phosphatase action. FEBS
Lett.
352:201-205.[CrossRef][Medline]
- 14 Brancho,
D., N. Tanaka, A. Jaeschke, J. J. Ventura, N. Kelkar, Y.
Tanaka, M. Kyuuma, T. Takeshita, R. A. Flavell, and
R. J. Davis. 2003. Mechanism of p38 MAP
kinase activation in vivo. Genes Dev.
17:1969-1978.[Abstract/Free Full Text]
- 15 Bruning,
J. C., J. A. Gillette, Y. Zhao, C. Bjorbaeck, J.
Kotzka, B. Knebel, H. Avci, B. Hanstein, P. Lingohr, D. E.
Moller, W. Krone, C. R. Kahn, and D. Muller-Wieland.2000
. Ribosomal subunit kinase-2 is required for growth
factor-stimulated transcription of the c-Fos gene. Proc. Natl.
Acad. Sci. USA
97:2462-2467.[Abstract/Free Full Text]
- 16 Bu,
X., D. W. Haas, and C. H. Hagedorn.1993
. Novel
phosphorylation sites of eukaryotic
initiation factor-4F and evidence that
phosphorylation stabilizes
interactions of the p25 and p220 subunits. J. Biol.
Chem.
268:4975-4978.[Abstract/Free Full Text]
- 17 Buck,
M., V. Poli, T. Hunter, and M. Chojkier. 2001.
C/EBPbeta phosphorylation by RSK
creates a functional XEXD caspase inhibitory box critical for cell
survival. Mol. Cell
8:807-816.[CrossRef][Medline]
- 18 Buck,
M., V. Poli, P. van der Geer, M. Chojkier, and T. Hunter.1999
. Phosphorylation of rat serine 105 or mouse threonine
217 in C/EBP beta is required for hepatocyte proliferation induced by
TGF alpha. Mol. Cell
4:1087-1092.[CrossRef][Medline]
- 19 Campbell,
S. L., R. Khosravi-Far, K. L. Rossman, G.
J. Clark, and C. J. Der. 1998. Increasing
complexity of Ras signaling. Oncogene
17:1395-1413.[CrossRef][Medline]
- 20 Cavet,
M. E., S. Lehoux, and B. C. Berk.2003
. 14-3-3beta is a p90 ribosomal S6
kinase (RSK) isoform 1-binding protein that negatively regulates RSK
kinase activity. J. Biol. Chem.
278:18376-18383.[Abstract/Free Full Text]
- 21 Chang,
C. I., B. E. Xu, R. Akella, M. H. Cobb,
and E. J. Goldsmith. 2002. Crystal
structures of MAP kinase p38 complexed to the docking sites on its
nuclear substrate MEF2A and activator MKK3b. Mol. Cell
9:1241-1249.[CrossRef][Medline]
- 22 Chen,
R.-H., C. Abate, and J. Blenis. 1993. Phosphorylation
of the c-Fos transrepression domain by mitogen-activated protein kinase
and 90-kDa ribosomal S6 kinase. Proc. Natl. Acad. Sci.
USA
90:10952-10956.[Abstract/Free Full Text]
- 23 Chen,
R. H., P. C. Juo, T. Curran, and J. Blenis.1996
. Phosphorylation of c-Fos at the C-terminus enhances
its transforming activity. Oncogene
12:1493-1502.[Medline]
- 24 Chen,
R.-H., C. Sarnecki, and J. Blenis. 1992. Nuclear
localization and regulation of the erk- and
rsk-encoded protein kinases. Mol. Cell. Biol.
12:915-927.[Abstract/Free Full Text]
- 25 Chen,
Z., T. B. Gibson, F. Robinson, L. Silvestro, G. Pearson, B.
Xu, A. Wright, C. Vanderbilt, and M. H. Cobb.2001
. MAP kinases. Chem. Rev.
101:2449-2476.[CrossRef][Medline]
- 26 Cheng,
T. J., and Y. K. Lai. 1998.
Identification of mitogen-activated protein kinase-activated protein
kinase-2 as a vimentin kinase activated by okadaic acid in 9L rat brain
tumor cells. J. Cell Biochem.
71:169-181.[CrossRef][Medline]
- 27 Chevalier,
D., and B. G. Allen. 2000. Two distinct
forms of MAPKAP kinase-2 in adult cardiac ventricular
myocytes. Biochemistry
39:6145-6156.[CrossRef][Medline]
- 28 Chong,
H., H. G. Vikis, and K. L. Guan.2003
. Mechanisms of regulating the Raf kinase family.Cell Signal.
15:463-469.[CrossRef][Medline]
- 29 Chrestensen,
C. A., and T. W. Sturgill. 2002.
Characterization of the p90 ribosomal S6 kinase 2 carboxyl-terminal
domain as a protein kinase. J. Biol. Chem.
277:27733-27741.[Abstract/Free Full Text]
- 30 Chung,
J., C. J. Kuo, G. R. Crabtree, and J. Blenis.1992
. Rapamycin-FKBP specifically blocks growth-dependent
activation of and signalling by the 70kD S6 protein kinases.Cell
69:1227-1236.[CrossRef][Medline]
- 31 Clayton,
A. L., and L. C. Mahadevan. 2003.
MAP kinase-mediated phosphoacetylation of histone H3 and inducible gene
regulation. FEBS Lett.
546:51-58.[CrossRef][Medline]
- 32 Clifton,
A. D., P. R. Young, and P. Cohen.1996
. A comparison of the substrate specificity of
MAPKAP kinase-2 and MAPKAP kinase-3 and their
activation by cytokines and cellular stress. FEBS Lett.
392:209-214.[CrossRef][Medline]
- 33 Cohen,
P., and S. Frame. 2001. The renaissance of GSK3.Nat. Rev. Mol. Cell. Biol.
2:769-776.[CrossRef][Medline]
- 34 Collins,
B. J., M. Deak, J. S. Arthur, L. J.
Armit, and D. R. Alessi. 2003. In vivo role
of the PIF-binding docking site of PDK1 defined by knock-in mutation.EMBO J.
22:4202-4211.[CrossRef][Medline]
- 35 Dalby,
K. N., N. Morrice, F. B. Caudwell, J. Avruch, and
P. Cohen. 1998. Identification of regulatory
phosphorylation sites in
mitogen-activated protein kinase (MAPK)-activated protein
kinase-1a/p90rsk that are inducible by MAPK.J. Biol. Chem.
273:1496-1505.[Abstract/Free Full Text]
- 36 Dan,
I., N. M. Watanabe, and A. Kusumi. 2001. The
Ste20 group kinases as regulators of MAP kinase cascades. Trends
Cell Biol.
11:220-230.[CrossRef][Medline]
- 37 Davie,
J. R. 2003. MSK1 and MSK2 mediate mitogen-
and stress-induced phosphorylation
of histone H3: a controversy resolved. Science STKE
2003:PE33.
- 38 Deak,
M., A. D. Clifton, L. M. Lucocq, and D.
R. Alessi. 1998. Mitogen- and stress-activated protein
kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38,
and may mediate activation of CREB. EMBO J.
17:4426-4441.[CrossRef][Medline]
- 39 De
Cesare, D., S. Jacquot, A. Hanauer, and P. Sassone-Corsi.1998
. Rsk-2 activity is necessary for epidermal growth
factor-induced phosphorylation of
CREB protein and transcription of c-fos gene. Proc. Natl. Acad.
Sci. USA
95:12202-12207.[Abstract/Free Full Text]
- 40 Delaunoy,
J., F. Abidi, M. Zeniou, S. Jacquot, K. Merienne, S. Pannetier, M.
Schmitt, C. Schwartz, and A. Hanauer. 2001. Mutations
in the X-linked RSK2 gene (RPS6KA3) in patients with Coffin-Lowry
syndrome. Hum. Mutat.
17:103-116.[CrossRef][Medline]
- 41 Douville,
E., and J. Downward. 1997. EGF induced SOS
phosphorylation in PC12 cells
involves P90 RSK-2. Oncogene
15:373-383.[CrossRef][Medline]
- 42 Downward,
J. 2003. Targeting RAS signalling pathways in cancer
therapy. Nat. Rev. Cancer
3:11-22.[CrossRef][Medline]
- 43 Dufresne,
S. D., C. Bjorbaek, K. El-Haschimi, Y. Zhao, W. G.
Aschenbach, D. E. Moller, and L. J. Goodyear.2001
. Altered extracellular signal-regulated kinase
signaling and glycogen metabolism in skeletal muscle from p90 ribosomal
S6 kinase 2 knockout mice. Mol. Cell. Biol.
21:81-87.[Abstract/Free Full Text]
- 44 Engel,
K., A. Kotlyarov, and M. Gaestel. 1998. Leptomycin
B-sensitive nuclear export of MAPKAP kinase 2 is regulated by
phosphorylation. EMBO
J.
17:3363-3371.[CrossRef][Medline]
- 45 Engel,
K., K. Plath, and M. Gaestel. 1993. The MAP
kinase-activated protein kinase 2 contains a proline-rich SH3-binding
domain. FEBS Lett.
336:143-147.[CrossRef][Medline]
- 46 Engel,
K., H. Schultz, F. Martin, A. Kotlyarov, K. Plath, M. Hahn, U.
Heinemann, and M. Gaestel. 1995. Constitutive
activation of mitogen-activated protein kinase-activated protein kinase
2 by mutation of phosphorylation
sites and an A-helix motif. J. Biol. Chem.
270:27213-27221.[Abstract/Free Full Text]
- 47 Enslen,
H., D. M. Brancho, and R. J. Davis.2000
. Molecular determinants that mediate selective
activation of p38 MAP kinase isoforms. EMBO J.
19:1301-1311.[CrossRef][Medline]
- 48 Enslen,
H., and R. J. Davis. 2001. Regulation of MAP
kinases by docking domains. Biol. Cell
93:5-14.[CrossRef][Medline]
- 49 Erikson,
E., and J. L. Maller. 1985. A protein kinase
from Xenopus eggs specific for ribosomal protein S6. Proc. Natl.
Acad. Sci. USA
82:742-746.[Abstract/Free Full Text]
- 50 Fantz,
D. A., D. Jacobs, D. Glossip, and K. Kornfeld.2001
. Docking sites on substrate proteins direct
extracellular signal-regulated kinase to phosphorylate specific
residues. J. Biol. Chem.
276:27256-27265.[Abstract/Free Full Text]
- 51 Fernando,
P., L. A. Megeney, and J. J. Heikkila.2003
. Phosphorylation-dependent structural alterations in
the small hsp30 chaperone are associated with cellular recovery.Exp. Cell Res.
286:175-185.[CrossRef][Medline]
- 52 Fisher,
T. L., and J. Blenis. 1996. Evidence for two
catalytically active kinase domains in pp90rsk. Mol.
Cell. Biol.
16:1212-1219.[Abstract]
- 53 Flynn,
A., R. G. Vries, and C. G. Proud.1997
. Signalling pathways which regulate eIF4E. Biochem.
Soc. Trans.
25:192S.
- 54 Freshney,
N. W., L. Rawlinson, F. Guesdon, E. Jones, S. Cowley, J.
Hsuan, and J. Saklatvala. 1994. Interleukin-1
activates a novel protein kinase cascade that results in the
phosphorylation of Hsp27.Cell
78:1039-1049.[CrossRef][Medline]
- 55 Frodin,
M., T. L. Antal, B. A. Dummler, C. J.
Jensen, M. Deak, S. Gammeltoft, and R. M. Biondi.2002
. A phosphoserine/threonine-binding pocket in AGC
kinases and PDK1 mediates activation by hydrophobic motif
phosphorylation. EMBO
J.
21:5396-5407.[CrossRef][Medline]
- 56 Frodin,
M., and S. Gammeltoft. 1999. Role and regulation of 90
kDa ribosomal S6 kinase (RSK) in signal transduction. Mol. Cell.
Endocrinol.
151:65-77.[CrossRef][Medline]
- 57 Frodin,
M., C. J. Jensen, K. Merienne, and S. Gammeltoft.2000
. A phosphoserine-regulated docking site in the
protein kinase RSK2 that recruits and activates PDK1. EMBO
J.
19:2924-2934.[CrossRef][Medline]
- 58 Fujita,
N., S. Sato, K. Katayama, and T. Tsuruo. 2002.
Akt-dependent phosphorylation of
p27Kip1 promotes binding to 14-3-3 and cytoplasmic
localization. J. Biol. Chem.
277:28706-28713.[Abstract/Free Full Text]
- 59 Fujita,
N., S. Sato, and T. Tsuruo. 2003. Phosphorylation of
p27Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes
its binding to 14-3-3 and cytoplasmic localization.J. Biol. Chem.
278:49254-49260.[Abstract/Free Full Text]
- 60 Fukunaga,
R., and T. Hunter. 1997. MNK1, a new MAP
kinase-activate protein kinase, isolated by a novel expression
screening method for identifying protein kinase substrates. EMBO
J.
16:1921-1997.[CrossRef][Medline]
- 61 Gao,
T., and A. C. Newton. 2002. The turn
motif is a phosphorylation switch
that regulates the binding of Hsp70 to protein kinase C. J.
Biol. Chem.
277:31585-31592.[Abstract/Free Full Text]
- 62 Gavin,
A. C., and A. R. Nebreda. 1999. A
MAP kinase docking site is required for
phosphorylation and activation of
p90(rsk)/MAPKAP kinase-1. Curr. Biol.
9:281-284.[CrossRef][Medline]
- 63 Geyer,
M., and A. Wittinghofer. 1997. GEFs, GAPs, GDIs and
effectors: taking a closer (3D) look at the regulation of Ras-related
GTP-binding proteins. Curr. Opin. Struct. Biol.
7:786-792.[CrossRef][Medline]
- 64 Ghoda,
L., X. Lin, and W. C. Greene. 1997. The
90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal
regulatory domain of IkappaBalpha and stimulates
its degradation in vitro. J. Biol. Chem.
272:21281-21288.[Abstract/Free Full Text]
- 65 Ginty,
D. D., A. Bonni, and M. E. Greenberg.1994
. Nerve growth factor activates a Ras-dependent
protein kinase that stimulates c-fos transcription via
phosphorylation of CREB.Cell
77:713-725.[CrossRef][Medline]
- 66 Gonzalez,
F. A., A. Seth, D. L. Raden, D. S.
Bowman, F. S. Fay, and R. J. Davis.1993
. Serum-induced translocation of mitogen-activated
protein kinase to the cell surface ruffling membrane and the nucleus.J. Cell Biol.
122:1089-1101.[Abstract/Free Full Text]
- 67 Gross,
S. D., A. L. Lewellyn, and J. L.
Maller. 2001. A constitutively active form of the
protein kinase p90Rsk1 is sufficient to trigger the G2/M
transition in Xenopus oocytes. J. Biol. Chem.
276:46099-46103.[Abstract/Free Full Text]
- 68 Gross,
S. D., M. S. Schwab, A. L. Lewellyn, and
J. L. Maller. 1999. Induction of metaphase
arrest in cleaving Xenopus embryos by the protein kinase p90Rsk.Science
286:1365-1367.[Abstract/Free Full Text]
- 69 Grzybowska,
E. A., A. Wilczynska, and J. A. Siedlecki.2001
. Regulatory functions of 3'UTRs.Biochem. Biophys. Res. Commun.
288:291-295.[CrossRef][Medline]
- 70 Guay,
J., H. Lambert, G. Gingras-Breton, J. N. Lavoie, J. Huot, and
J. Landry. 1997. Regulation of actin filament dynamics
by p38 map kinase-mediated
phosphorylation of heat shock
protein 27. J. Cell Sci.
110:357-368.[Abstract]
- 71 Hallberg,
B., S. I. Rayter, and J. Downward. 1994.
Interaction of Ras and Raf in intact mammalian cells upon extracellular
stimulation. J. Biol. Chem.
269:3913-3916.[Abstract/Free Full Text]
- 72 Hamm,
J., D. R. Alessi, and R. M. Biondi.2002
. Bi-functional, substrate mimicking RNA inhibits
MSK1-mediated cAMP-response element-binding protein
phosphorylation and reveals
magnesium ion-dependent conformational changes of the kinase.J. Biol. Chem.
277:45793-45802.[Abstract/Free Full Text]
- 73 Han,
J., J. D. Lee, L. Bibbs, and R. J. Ulevitch.1994
. A MAP kinase targeted by endotoxin and
hyperosmolarity in mammalian cells. Science
265:808-811.[Abstract/Free Full Text]
- 74 Han,
Q., J. Leng, D. Bian, C. Mahanivong, K. A. Carpenter,
Z. K. Pan, J. Han, and S. Huang. 2002.
Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen
activator mRNA stability in invasive breast cancer cells.J. Biol. Chem.
277:48379-48385.[Abstract/Free Full Text]
- 75 Hannigan,
M. O., L. Zhan, Y. Ai, A. Kotlyarov, M. Gaestel, and
C. K. Huang. 2001. Abnormal migration
phenotype of mitogen-activated protein kinase-activated protein kinase
2-/- neutrophils in Zigmond chambers containing
formyl-methionyl-leucyl-phenylalanine gradients. J.
Immunol.
167:3953-3961.[Abstract/Free Full Text]
- 76 Hedges,
J. C., M. A. Dechert, I. A. Yamboliev,
J. L. Martin, E. Hickey, L. A. Weber, and
W. T. Gerthoffer. 1999. A role for
p38(MAPK)/HSP27 pathway in smooth muscle cell migration.J. Biol. Chem.
274:24211-24219.[Abstract/Free Full Text]
- 77 Heidenreich,
O., A. Neininger, G. Schratt, R. Zinck, M. A. Cahill, K.
Engel, A. Kotlyarov, R. Kraft, S. Kostka, M. Gaestel, and A.
Nordheim. 1999. MAPKAP kinase 2
phosphorylates serum response factor in vitro and in vivo.J. Biol. Chem.
274:14434-14443.[Abstract/Free Full Text]
- 78 Hill,
M. M., J. Feng, and B. A. Hemmings.2002
. Identification of a plasma membrane Raft-associated
PKB Ser473 kinase activity that is distinct from ILK and PDK1.Curr. Biol.
12:1251-1255.[CrossRef][Medline]
- 79 Hsiao,
K.-M., S.-Y. Chou, S.-J. Shih, and J. E. Ferrell, Jr.1994
. Evidence that inactive p42 mitogen-activated protein
kinase and inactive Rsk exist as a heterodimer in vivo.Proc. Natl. Acad. Sci. USA
91:5480-5484.[Abstract/Free Full Text]
- 80 Huang,
C. K., L. Zhan, Y. Ai, and J. Jongstra.1997
. LSP1 is the major substrate for mitogen-activated
protein kinase-activated protein kinase 2 in human neutrophils.J. Biol. Chem.
272:17-19.[Abstract/Free Full Text]
- 81 Jacobs,
D., G. J. Beitel, S. G. Clark, H. R.
Horvitz, and K. Kornfeld. 1998. Gain-of-function
mutations in the Caenorhabditis elegans lin-1 ETS gene identify a
C-terminal regulatory domain
phosphorylated by ERK MAP kinase.Genetics
149:1809-1822.[Abstract/Free Full Text]
- 82 Jacobs,
D., D. Glossip, H. Xing, A. J. Muslin, and K. Kornfeld.1999
. Multiple docking sites on substrate proteins form a
modular system that mediates recognition by ERK MAP kinase.Genes Dev.
13:163-175.[Abstract/Free Full Text]
- 83 Jacquot,
S., K. Merienne, D. De Cesare, S. Pannetier, J. L. Mandel, P.
Sassone-Corsi, and A. Hanauer. 1998. Mutation analysis
of the RSK2 gene in Coffin-Lowry patients: extensive allelic
heterogeneity and a high rate of de novo mutations.Am. J. Hum. Genet.
63:1631-1640.[CrossRef][Medline]
- 84 Jacquot,
S., K. Merienne, E. Trivier, M. Zeniou, S. Pannetier, and A.
Hanauer. 1999. Coffin-Lowry syndrome: current status.Am. J. Med. Genet.
85:214-215.[CrossRef][Medline]
- 85 Janknecht,
R. 2001. Cell type-specific inhibition of the
ETS transcription factor ER81 by mitogen-activated protein
kinase-activated protein kinase 2. J. Biol. Chem.
276:41856-41861.[Abstract/Free Full Text]
- 86 Janknecht,
R. 2003. Regulation of the ER81 transcription factor
and its coactivators by mitogen- and stress-activated protein kinase 1
(MSK1). Oncogene
22:746-755.[CrossRef][Medline]
- 87 Jefferies,
H. B., S. Fumagalli, P. B. Dennis, C. Reinhard,
R. B. Pearson, and G. Thomas. 1997.
Rapamycin suppresses 5'TOP mRNA translation through
inhibition of p70s6k. EMBO J.
16:3693-3704.[CrossRef][Medline]
- 88 Jensen,
C. J., M. B. Buch, T. O. Krag,
B. A. Hemmings, S. Gammeltoft, and M. Frodin.1999
. 90-kDa ribosomal S6 kinase is
phosphorylated and activated by
3-phosphoinositide-dependent protein kinase-1. J.
Biol. Chem.
274:27168-27176.[Abstract/Free Full Text]
- 89 Jin,
Y., Y. Wang, D. L. Walker, H. Dong, C. Conley, J. Johansen,
and K. M. Johansen. 1999. JIL-1: a novel
chromosomal tandem kinase implicated in transcriptional regulation in
Drosophila. Mol. Cell
4:129-135.[CrossRef][Medline]
- 90 Joel,
P. B., J. Smith, T. W. Sturgill, T. L.
Fisher, J. Blenis, and D. A. Lannigan. 1998.
pp90rsk1 regulates estrogen receptor-mediated transcription
through phosphorylation of Ser-167.Mol. Cell. Biol.
18:1978-1984.[Abstract/Free Full Text]
- 91 Jones,
S. W., E. Erikson, J. Blenis, J. L. Maller, and
R. L. Erikson. 1988. A Xenopus ribosomal
protein S6 kinase has two apparent kinase domains that are each similar
to distinct protein kinases. Proc. Natl. Acad. Sci. USA
85:3377-3381.[Abstract/Free Full Text]
- 92 Katsanis,
N., J. R. Lupski, and P. L. Beales.2001
. Exploring the molecular basis of Bardet-Biedl
syndrome. Hum. Mol. Genet.
10:2293-2299.[Abstract/Free Full Text]
- 93 Kidd,
D., and J. W. Raff. 1997. LK6, a short lived
protein kinase in Drosophila that can associate with microtubules and
centrosomes. J. Cell Sci.
110:209-219.[Abstract]
- 94 Kinuya,
M., K. Takishima, and G. Mamiya. 2000. Detection of
kinases that phosphorylate 14-3-3 binding sites of
Raf-1 using in situ gel kinase assay. Biol. Pharm. Bull.
23:1158-1162.[Medline]
- 95 Knauf,
U., C. Tschopp, and H. Gram. 2001. Negative
regulation of protein translation by mitogen-activated protein
kinase-interacting kinases 1 and 2. Mol. Cell. Biol.
21:5500-5511.[Abstract/Free Full Text]
- 96 Knebel,
A., C. E. Haydon, N. Morrice, and P. Cohen.2002
. Stress-induced regulation of eukaryotic elongation
factor 2 kinase by SB 203580-sensitive and -insensitive pathways.Biochem. J.
367:525-532.[CrossRef][Medline]
- 97 Kohno,
M., and J. Pouyssegur. 2003. Pharmacological
inhibitors of the ERK signaling pathway: application as anticancer
drugs. Prog. Cell Cycle Res.
5:219-224.
- 98 Kolch,
W. 2000. Meaningful relationships: the regulation of
the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem
J.
351:289-305.[CrossRef][Medline]
- 99 Kontoyiannis,
D., A. Kotlyarov, E. Carballo, L. Alexopoulou, P. J.
Blackshear, M. Gaestel, R. Davis, R. Flavell, and G. Kollias.2001
. Interleukin-10 targets p38 MAPK to modulate
ARE-dependent TNF mRNA translation and limit intestinal
pathology. EMBO J.
20:3760-3770.[CrossRef][Medline]
- 100 Kotlyarov,
A., and M. Gaestel. 2002. Is MK2 (mitogen-activated
protein kinase-activated protein kinase 2) the key for understanding
post-transcriptional regulation of gene expression? Biochem.
Soc. Trans.
30:959-963.[CrossRef][Medline]
- 101 Kotlyarov,
A., A. Neininger, C. Schubert, R. Eckert, C. Birchmeier, H.
D. Volk, and M. Gaestel. 1999. MAPKAP kinase
2 is essential for LPS-induced TNF-alpha biosynthesis. Nat. Cell
Biol.
1:94-97.[CrossRef][Medline]
- 102 Kotlyarov,
A., Y. Yannoni, S. Fritz, K. Laass, J. B. Telliez, D. Pitman,
L. L. Lin, and M. Gaestel. 2002. Distinct
cellular functions of MK2. Mol. Cell. Biol.
22:4827-4835.[Abstract/Free Full Text]
- 103 Kyriakis,
J. M., and J. Avruch. 2001. Mammalian
mitogen-activated protein kinase signal transduction pathways activated
by stress and inflammation. Physiol. Rev.
81:807-869.[Abstract/Free Full Text]
- 104 Kyriakis,
J. M., and J. Avruch. 1990. pp54
microtubule-associated protein 2 kinase. A novel serine/threonine
protein kinase regulated by
phosphorylation and stimulated by
poly-L-lysine. J. Biol. Chem.
265:17355-17363.[Abstract/Free Full Text]
- 105 Lambert,
H., S. J. Charette, A. F. Bernier, A. Guimond, and
J. Landry. 1999. HSP27 multimerization mediated by
phosphorylation-sensitive
intermolecular interactions at the amino terminus. J.
Biol. Chem.
274:9378-9385.[Abstract/Free Full Text]
- 106 Larochelle,
S., and B. Suter. 1995. The Drosophila melanogaster
homolog of the mammalian MAPK-activated protein kinase-2
(MAPKAPK-2) lacks a proline-rich N-terminus.Gene
163:209-214.[CrossRef][Medline]
- 107 Lee,
C. W., J. S. Nam, Y. K. Park,
H. K. Choi, J. H. Lee, N. H. Kim,
J. Cho, D. K. Song, H. W. Suh, J. Lee,
Y. H. Kim, and S. O. Huh. 2003.
Lysophosphatidic acid stimulates CREB through mitogen- and
stress-activated protein kinase-1. Biochem. Biophys. Res.
Commun.
305:455-461.[CrossRef][Medline]
- 108 Lee,
J. C., J. T. Laydon, P. C. McDonnell,
T. F. Gallagher, S. Kumar, D. Green, D. McNulty, M.
J. Blumenthal, J. R. Heys, S. W. Landvatter, and et
al. 1994. A protein kinase involved in the regulation
of inflammatory cytokine biosynthesis. Nature
372:739-746.[CrossRef][Medline]
- 109 Lehner,
M. D., F. Schwoebel, A. Kotlyarov, M. Leist, M. Gaestel, and
T. Hartung. 2002. Mitogen-activated protein
kinase-activated protein kinase 2-deficient mice show increased
susceptibility to Listeria monocytogenes infection. J.
Immunol.
168:4667-4673.[Abstract/Free Full Text]
- 110 Leighton,
I. A., K. N. Dalby, F. B. Caudwell,
P. T. Cohen, and P. Cohen. 1995. Comparison
of the specificities of p70 S6 kinase and MAPKAP kinase-1
identifies a relatively specific substrate for p70 S6 kinase: the
N-terminal kinase domain of MAPKAP kinase-1 is essential for
peptide phosphorylation.FEBS Lett.
375:289-293.[CrossRef][Medline]
- 111 Lenormand,
P., C. Sardet, G. Pages, G. L'Allemain, A. Brunet, and J.
Pouyssegur. 1993. Growth factors induce nuclear
translocation of MAP kinases (p42mapk and p44mapk) but not of their
activator MAP kinase kinase (p45mapkk) in fibroblasts.J. Cell Biol.
122:1079-1088.[Abstract/Free Full Text]
- 112 Lewis,
T. S., P. S. Shapiro, and N. G. Ahn.1998
. Signal transduction through MAP kinase cascades.Adv. Cancer Res.
74:49-139.[Medline]
- 113 Li,
Y., K. Inoki, P. Vacratsis, and K. L. Guan.2003
. The p38 and MK2 kinase cascade phosphorylates
tuberin, the tuberous sclerosis 2 gene product, and enhances its
interaction with 14-3-3. J. Biol.
Chem.
278:13663-13671.[Abstract/Free Full Text]
- 114 Liu,
G., Y. Zhang, A. M. Bode, W. Y. Ma, and Z.
Dong. 2002. Phosphorylation of 4E-BP1 is mediated by
the p38/MSK1 pathway in response to UVB irradiation.J. Biol. Chem.
277:8810-8816.[Abstract/Free Full Text]
- 115 Lizcano,
J. M., O. Goransson, R. Toth, M. Deak, N. A.
Morrice, J. Boudeau, S. A. Hawley, L. Udd, T. P.
Makela, D. G. Hardie, and D. R. Alessi.2004
. LKB1 is a master kinase that activates 13 kinases of
the AMPK subfamily, including MARK/PAR-1. EMBO J.
23:833-843.[CrossRef][Medline]
- 116 Lonze,
B. E., and D. D. Ginty. 2002.
Function and regulation of CREB family transcription factors in the
nervous system. Neuron
35:605-623.[CrossRef][Medline]
- 117 Ludwig,
S., K. Engel, A. Hoffmeyer, G. Sithanandam, B. Neufeld, D. Palm, M.
Gaestel, and U. R. Rapp. 1996. 3pK, a novel
mitogen-activated protein (MAP) kinase-activated protein kinase, is
targeted by three MAP kinase pathways. Mol. Cell. Biol.
16:6687-6697.[Abstract]
- 118 Madhani,
H. D., and G. R. Fink. 1998. The
riddle of MAP kinase signaling specificity. Trends
Genet.
14:151-155.[CrossRef][Medline]
- 119 Mahtani,
K. R., M. Brook, J. L. Dean, G. Sully, J.
Saklatvala, and A. R. Clark. 2001.
Mitogen-activated protein kinase p38 controls the expression and
posttranslational modification of tristetraprolin, a regulator of tumor
necrosis factor alpha mRNA stability. Mol. Cell.
Biol.
21:6461-6469.[Abstract/Free Full Text]
- 120 Martin,
K. A., and J. Blenis. 2002. Coordinate
regulation of translation by the PI 3-kinase and mTOR pathways.Adv. Cancer Res.
86:1-39.[Medline]
- 121 McKendrick,
L., E. Thompson, J. Ferreira, S. J. Morley, and J.
D. Lewis. 2001. Interaction of eukaryotic translation
initiation factor 4G with the nuclear cap-binding complex provides a
link between nuclear and cytoplasmic functions of the m7
guanosine cap. Mol. Cell. Biol.
21:3632-3641.[Abstract/Free Full Text]
- 122 McLaughlin,
M. M., S. Kumar, P. C. McDonnell, S. Van Horn,
J. C. Lee, G. P. Livi, and P. R.
Young. 1996. Identification of mitogen-activated
protein (MAP) kinase-activated protein kinase-3, a novel substrate of
CSBP p38 MAP kinase. J. Biol. Chem.
271:8488-8492.[Abstract/Free Full Text]
- 123 Meier,
R., J. Rouse, A. Cuenda, A. R. Nebreda, and P. Cohen.1996
. Cellular stresses and cytokines activate multiple
mitogen-activated-protein kinase kinase homologues in PC12 and KB
cells. Eur. J. Biochem.
236:796-805.[Abstract]
- 124 Meng,
W., L. L. Swenson, M. J. Fitzgibbon, K. Hayakawa,
E. Ter Haar, A. E. Behrens, J. R. Fulghum, and
J. A. Lippke. 2002. Structure of
mitogen-activated protein kinase-activated protein (MAPKAP)
kinase 2 suggests a bifunctional switch that couples kinase activation
with nuclear export. J. Biol. Chem.
277:37401-37405.[Abstract/Free Full Text]
- 125 Mercer,
K. E., and C. A. Pritchard. 2003.
Raf proteins and cancer: B-Raf is identified as a mutational target.Biochim. Biophys. Acta
1653:25-40.[Medline]
- 126 Minich,
W. B., M. L. Balasta, D. J. Goss, and
R. E. Rhoads. 1994. Chromatographic
resolution of in vivo
phosphorylated and
nonphosphorylated eukaryotic
translation initiation factor eIF-4E: increased cap affinity of the
phosphorylated form. Proc.
Natl. Acad. Sci. USA
91:7668-7672.[Abstract/Free Full Text]
- 127 Mizukami,
Y., K. Yoshioka, S. Morimoto, and K. Yoshida. 1997. A
novel mechanism of JNK1 activation. Nuclear translocation and
activation of JNK1 during ischemia and reperfusion. J.
Biol. Chem.
272:16657-16662.[Abstract/Free Full Text]
- 128 Murphy,
L. O., J. P. MacKeigan, and J. Blenis.2004
. A network of immediate early gene products
propagates subtle differences in mitogen-activated protein kinase
signal amplitude and duration. Mol. Cell. Biol.
24:144-153.[Abstract/Free Full Text]
- 129 Murphy,
L. O., S. Smith, R. H. Chen, D. C.
Fingar, and J. Blenis. 2002. Molecular interpretation
of ERK signal duration by immediate early gene products. Nat.
Cell Biol.
4:556-564.[Medline]
- 130 Nakajima,
T., A. Fukamizu, J. Takahashi, F. H. Gage, T. Fisher, J.
Blenis, and M. R. Montminy. 1996. The
signal-dependent coactivator CBP is a nuclear target for pp90RSK.Cell
86:465-474.[CrossRef][Medline]
- 131 Nebreda,
A. R., and I. Ferby. 2000. Regulation of the
meiotic cell cycle in oocytes. Curr. Opin. Cell Biol.
12:666-675.[CrossRef][Medline]
- 132 Neininger,
A., D. Kontoyiannis, A. Kotlyarov, R. Winzen, R. Eckert, H.
D. Volk, H. Holtmann, G. Kollias, and M. Gaestel.2002
. MK2 targets AU-rich elements and regulates
biosynthesis of tumor necrosis factor and interleukin-6 independently
at different post-transcriptional levels. J. Biol.
Chem.
277:3065-3068.[Abstract/Free Full Text]
- 133 Neininger,
A., H. Thielemann, and M. Gaestel. 2001. FRET-based
detection of different conformations of MK2. EMBO Rep.
2:703-708.[CrossRef][Medline]
- 134 Neufeld,
B., A. Grosse-Wilde, A. Hoffmeyer, B. W. Jordan, P. Chen, D.
Dinev, S. Ludwig, and U. R. Rapp. 2000.
Serine/threonine kinases 3pK and MAPK-activated protein kinase
2 interact with the basic helix-loop-helix transcription factor E47 and
repress its transcriptional activity. J. Biol.
Chem.
275:20239-20242.[Abstract/Free Full Text]
- 135 New,
L., Y. Jiang, and J. Han. 2003. Regulation of PRAK
subcellular location by p38 MAP kinases. Mol. Biol. Cell
14:2603-2616.[Abstract/Free Full Text]
- 136 New,
L., Y. Jiang, M. Zhao, K. Liu, W. Zhu, L. J. Flood, Y. Kato,
G. C. Parry, and J. Han. 1998. PRAK, a novel
protein kinase regulated by the p38 MAP kinase. EMBO J.
17:3372-3384.[CrossRef][Medline]
- 137 New,
L., M. Zhao, Y. Li, W. W. Bassett, Y. Feng, S. Ludwig,
F. D. Padova, H. Gram, and J. Han. 1999.
Cloning and characterization of RLPK, a novel RSK-related protein
kinase. J. Biol. Chem.
274:1026-1032.[Abstract/Free Full Text]
- 138 Newton,
A. C. 2003. Regulation of the ABC kinases by
phosphorylation: protein kinase C
as a paradigm. Biochem. J.
370:361-371.[CrossRef][Medline]
- 139 Ni,
H., X. S. Wang, K. Diener, and Z. Yao. 1998.
MAPKAPK5, a novel mitogen-activated protein kinase
(MAPK)-activated protein kinase, is a substrate of the
extracellular-regulated kinase (ERK) and p38 kinase. Biochem.
Biophys. Res. Commun.
243:492-496.[CrossRef][Medline]
- 140 Nomura,
M., A. Kaji, W. Y. Ma, S. Zhong, G. Liu, G. T.
Bowden, K. I. Miyamoto, and Z. Dong. 2001.
Mitogen- and stress-activated protein kinase 1 mediates activation of
Akt by ultraviolet B irradiation. J. Biol.
Chem.
276:25558-25567.[Abstract/Free Full Text]
- 141 Okazaki,
K., and N. Sagata. 1995. The Mos/MAP kinase pathway
stabilizes c-Fos by phosphorylation
and augments its transforming activity in NIH 3T3 cells. EMBO
J.
14:5048-5059.[Medline]
- 142 Okumura,
E., T. Fukuhara, H. Yoshida, S. Hanada Si, R. Kozutsumi, M. Mori, K.
Tachibana, and T. Kishimoto. 2002. Akt inhibits Myt1
in the signalling pathway that leads to meiotic G2/M-phase transition.Nat. Cell Biol.
4:111-116.[CrossRef][Medline]
- 143 Ono,
K., and J. Han. 2000. The p38 signal transduction
pathway: activation and function. Cell Signal.
12:1-13.[CrossRef][Medline]
- 144 Palmer,
A., A. C. Gavin, and A. R. Nebreda.1998
. A link between MAP kinase and p34(cdc2)/cyclin B
during oocyte maturation: p90(rsk) phosphorylates and inactivates the
p34(cdc2) inhibitory kinase Myt1. EMBO J.
17:5037-5047.[CrossRef][Medline]
- 145 Park,
H. Y., and B. A. Gilchrest. 2002.
More on MITF. J. Investig. Dermatol.
119:1218-1219.[CrossRef][Medline]
- 146 Parra-Palau,
J. L., G. C. Scheper, M. L. Wilson, and
C. G. Proud. 2003. Features in the N- and
C-termini of the MAP kinase-interacting kinase Mnk1 mediate its
nucleocytoplasmic shuttling. J. Biol. Chem.
278:44197-44204.
- 147 Pearson,
G., F. Robinson, T. Beers Gibson, B. E. Xu, M. Karandikar, K.
Berman, and M. H. Cobb. 2001.
Mitogen-activated protein (MAP) kinase pathways: regulation and
physiological functions. Endocrinol. Rev.
22:153-183.[Abstract/Free Full Text]
- 148 Peyssonnaux,
C., and A. Eychene. 2001. The Raf/MEK/ERK pathway: new
concepts of activation. Biol. Cell
93:53-62.[CrossRef][Medline]
- 149 Pierrat,
B., J. S. Correia, J. L. Mary, M. Tomas-Zuber, and
W. Lesslauer. 1998. RSK-B, a novel ribosomal S6 kinase
family member, is a CREB kinase under dominant control of p38alpha
mitogen-activated protein kinase (p38alphaMAPK).J. Biol. Chem.
273:29661-29671.[Abstract/Free Full Text]
- 150 Piotrowicz,
R. S., E. Hickey, and E. G. Levin.1998
. Heat shock protein 27 kDa expression and
phosphorylation regulates
endothelial cell migration. FASEB J.
12:1481-1490.[Abstract/Free Full Text]
- 151 Plath,
K., K. Engel, G. Schwedersky, and M. Gaestel. 1994.
Characterization of the proline-rich region of mouse MAPKAP
kinase 2: influence on catalytic properties and binding to the c-abl
SH3 domain in vitro. Biochem. Biophys. Res. Commun.
203:1188-1194.[CrossRef][Medline]
- 152 Pouyssegur,
J., V. Volmat, and P. Lenormand. 2002. Fidelity and
spatio-temporal control in MAP kinase (ERKs) signalling.Biochem. Pharmacol.
64:755-763.[CrossRef][Medline]
- 153 Powell,
D. W., M. J. Rane, B. A. Joughin, R.
Kalmukova, J. H. Hong, B. Tidor, W. L. Dean,
W. M. Pierce, J. B. Klein, M. B. Yaffe,
and K. R. McLeish. 2003. Proteomic
identification of 14-3-3
as a
mitogen-activated protein kinase-activated protein kinase 2 substrate:
role in dimer formation and ligand binding. Mol. Cell.
Biol.
23:5376-5387.[Abstract/Free Full Text]
- 154 Pyronnet,
S., H. Imataka, A. C. Gingras, R. Fukunaga, T. Hunter, and N.
Sonenberg. 1999. Human eukaryotic translation
initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E.EMBO J.
18:270-279.[CrossRef][Medline]
- 155 Quan,
L. T., A. Caputo, R. C. Bleackley, D. J.
Pickup, and G. S. Salvesen. 1995.Granzyme B is inhibited by the cowpox virus serpin cytokine
response modifier A. J. Biol. Chem.
270:10377-10379.[Abstract/Free Full Text]
- 156 Raingeaud,
J., S. Gupta, J. S. Rogers, M. Dickens, J. Han, R.
J. Ulevitch, and R. J. Davis. 1995.
Pro-inflammatory cytokines and environmental stress cause p38
mitogen-activated protein kinase activation by dual
phosphorylation on tyrosine and
threonine. J. Biol. Chem.
270:7420-7426.[Abstract/Free Full Text]
- 157 Ramne,
A., E. Bilsland-Marchesan, S. Erickson, and P. Sunnerhagen.2000
. The protein kinases Rck1 and Rck2 inhibit meiosis in
budding yeast. Mol. Gen. Genet.
263:253-261.[CrossRef][Medline]
- 158 Rane,
M. J., P. Y. Coxon, D. W. Powell, R.
Webster, J. B. Klein, W. Pierce, P. Ping, and K. R.
McLeish. 2001. p38 Kinase-dependent MAPKAPK-2
activation functions as 3-phosphoinositide-dependent kinase-2 for Akt
in human neutrophils. J. Biol. Chem.
276:3517-3523.[Abstract/Free Full Text]
- 159 Richards,
S. A., V. C. Dreisbach, L. O. Murphy, and
J. Blenis. 2001. Characterization of regulatory
events associated with membrane targeting of p90 ribosomal S6 kinase 1.Mol. Cell. Biol.
21:7470-7480.[Abstract/Free Full Text]
- 160 Richards,
S. A., J. Fu, A. Romanelli, A. Shimamura, and J. Blenis.1999
. Ribosomal S6 kinase 1 (RSK1) activation requires
signals dependent on and independent of the MAP kinase ERK.Curr. Biol.
9:810-820.[CrossRef][Medline]
- 161 Rivera,
V. M., C. K. Miranti, R. P. Misra,
D. D. Ginty, R. H. Chen, J. Blenis, and
M. E. Greenberg. 1993. A growth
factor-induced kinase phosphorylates the serum response factor at a
site that regulates its DNA-binding activity. Mol. Cell.
Biol.
13:6260-6273.[Abstract/Free Full Text]
- 162 Rogalla,
T., M. Ehrnsperger, X. Preville, A. Kotlyarov, G. Lutsch, C. Ducasse,
C. Paul, M. Wieske, A. P. Arrigo, J. Buchner, and M.
Gaestel. 1999. Regulation of Hsp27 oligomerization,
chaperone function, and protective activity against oxidative
stress/tumor necrosis factor alpha by
phosphorylation.J. Biol. Chem.
274:18947-18956.[Abstract/Free Full Text]
- 163 Rouse,
J., P. Cohen, S. Trigon, M. Morange, A. Alonso-Llamazares, D.
Zamanillo, T. Hunt, and A. R. Nebreda. 1994.
A novel kinase cascade triggered by stress and heat shock that
stimulates MAPKAP kinase-2 and
phosphorylation of the small heat
shock proteins. Cell
78:1027-1037.[CrossRef][Medline]
- 164 Rousseau,
S., N. Morrice, M. Peggie, D. G. Campbell, M. Gaestel, and P.
Cohen. 2002. Inhibition of SAPK2a/p38 prevents hnRNP
A0 phosphorylation by
MAPKAP-K2 and its interaction with cytokine mRNAs.EMBO J.
21:6505-6514.[CrossRef][Medline]
- 165 Roux,
P. P., S. A. Richards, and J. Blenis.2003
. Phosphorylation of p90 ribosomal S6 kinase (RSK)
regulates extracellular signal-regulated kinase docking and RSK
activity. Mol. Cell. Biol.
23:4796-4804.[Abstract/Free Full Text]
- 166 Rubinfeld,
H., T. Hanoch, and R. Seger. 1999. Identification of a
cytoplasmic-retention sequence in ERK2. J. Biol.
Chem.
274:30349-30352.[Abstract/Free Full Text]
- 167 Sapkota,
G. P., A. Kieloch, J. M. Lizcano, S. Lain,
J. S. Arthur, M. R. Williams, N. Morrice, M. Deak,
and D. R. Alessi. 2001. Phosphorylation of
the protein kinase mutated in Peutz-Jeghers cancer syndrome,
LKB1/STK11, at Ser431 by p90(RSK) and cAMP-dependent protein kinase,
but not its farnesylation at Cys(433), is essential for LKB1 to
suppress cell growth. J. Biol. Chem.
276:19469-19482.[Abstract/Free Full Text]
- 168 Sassone-Corsi,
P., C. A. Mizzen, P. Cheung, C. Crosio, L. Monaco, S.
Jacquot, A. Hanauer, and C. D. Allis. 1999.
Requirement of Rsk-2 for epidermal growth factor-activated
phosphorylation of histone H3.Science
285:886-891.[Abstract/Free Full Text]
- 169 Scheper,
G. C., N. A. Morrice, M. Kleijn, and C.
G. Proud. 2001. The mitogen-activated protein kinase
signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E
kinase with high levels of basal activity in mammalian cells.Mol. Cell. Biol.
21:743-754.[Abstract/Free Full Text]
- 170 Scheper,
G. C., J. L. Parra, M. Wilson, B. Van Kollenburg,
A. C. Vertegaal, Z. G. Han, and C. G.
Proud. 2003. The N and C termini of the splice
variants of the human mitogen-activated protein kinase-interacting
kinase Mnk2 determine activity and localization. Mol. Cell.
Biol.
23:5692-5705.[Abstract/Free Full Text]
- 171 Scheper,
G. C., and C. G. Proud. 2002. Does
phosphorylation of the cap-binding
protein eIF4E play a role in translation initiation? Eur.
J. Biochem.
269:5350-5359.[Abstract/Free Full Text]
- 172 Scheper,
G. C., B. van Kollenburg, J. Hu, Y. Luo, D. J.
Goss, and C. G. Proud. 2002. Phosphorylation
of eukaryotic initiation factor 4E markedly reduces its affinity for
capped mRNA. J. Biol. Chem.
277:3303-3309.[Abstract/Free Full Text]
- 173 Schmitt,
A., G. J. Gutierrez, P. Lenart, J. Ellenberg, and
A. R. Nebreda. 2002. Histone H3
phosphorylation during Xenopus
oocyte maturation: regulation by the MAP kinase/p90Rsk pathway and
uncoupling from DNA condensation. FEBS Lett.
518:23-28.[CrossRef][Medline]
- 174 Schmitt,
A., and A. R. Nebreda. 2002. Signalling
pathways in oocyte meiotic maturation. J. Cell
Sci.
115:2457-2459.[Free Full Text]
- 175 Schouten,
G. J., A. C. O. Vertegaal, S.
T. Whiteside, A. Israel, M. Toebes, J. C. Dorsman,
A. J. van der Eb, and A. Zantema. 1997.
I
B
is a target for the mitogen-activated 90 kDa
ribosomal S6 kinase. EMBO J.
16:3133-3144.[CrossRef][Medline]
- 176 Schuck,
S., A. Soloaga, G. Schratt, J. S. Arthur, and A.
Nordheim. 2003. The kinase MSK1 is required for
induction of c-fos by lysophosphatidic acid in mouse embryonic stem
cells. BMC Mol. Biol.
4:6.
- 177 Schwab,
M. S., B. T. Roberts, S. D. Gross,
B. J. Tunquist, F. E. Taieb, A. L.
Lewellyn, and J. L. Maller. 2001. Bub1 is
activated by the protein kinase p90(Rsk) during Xenopus oocyte
maturation. Curr. Biol.
11:141-150.[CrossRef][Medline]
- 178 Scimeca,
J. C., T. T. Nguyen, C. Filloux, and E. Van
Obbergen. 1992. Nerve growth factor-induced
phosphorylation cascade in PC12
pheochromocytoma cells. Association of S6 kinase II with the
mictrotubule-associated protein kinase, ERK1. J. Biol.
Chem.
267:17369-17374.[Abstract/Free Full Text]
- 179 Seternes,
O. M., B. Johansen, B. Hegge, M. Johannessen, S. M.
Keyse, and U. Moens. 2002. Both binding and activation
of p38 mitogen-activated protein kinase (MAPK) play essential
roles in regulation of the nucleocytoplasmic distribution of
MAPK-activated protein kinase 5 by cellular stress.Mol. Cell. Biol.
22:6931-6945.[Abstract/Free Full Text]
- 180 Sharrocks,
A. D., S. H. Yang, and A. Galanis.2000
. Docking domains and substrate-specificity
determination for MAP kinases. Trends Biochem. Sci.
25:448-453.[CrossRef][Medline]
- 181 Shaw,
R. J., M. Kosmatka, N. Bardeesy, R. L. Hurley,
L. A. Witters, R. A. DePinho, and L. C.
Cantley. 2004. The tumor suppressor LKB1 kinase
directly activates AMP-activated kinase and regulates
apoptosis in response to energy stress. Proc.
Natl. Acad. Sci. USA
101:3329-3335.[Abstract/Free Full Text]
- 182 She,
Q. B., W. Y. Ma, S. Zhong, and Z. Dong.2002
. Activation of JNK1, RSK2, and MSK1 is involved in
serine 112 phosphorylation of Bad
by ultraviolet B radiation. J. Biol. Chem.
277:24039-24048.[Abstract/Free Full Text]
- 183 Shi,
Y., A. Kotlyarov, K. Laabeta, A. D. Gruber, E. Butt, K.
Marcus, H. E. Meyer, A. Friedrich, H. D. Volk, and
M. Gaestel. 2003. Elimination of protein kinase
MK5/PRAK activity by targeted homologous recombination. Mol.
Cell. Biol.
23:7732-7741.[Abstract/Free Full Text]
- 184 Shimamura,
A., B. A. Ballif, S. A. Richards, and J.
Blenis. 2000. Rsk1 mediates a MEK-MAP kinase cell
survival signal. Curr. Biol.
10:127-135.[CrossRef][Medline]
- 185 Singh,
S., D. W. Powell, M. J. Rane, T. H.
Millard, J. O. Trent, W. M. Pierce, J. B.
Klein, L. M. Machesky, and K. R. McLeish.2003
. Identification of the p16-Arc subunit of the Arp 2/3
complex as a substrate of MAPK-activated protein kinase 2 by
proteomic analysis. J. Biol. Chem.
278:36410-36417.[Abstract/Free Full Text]
- 186 Sithanandam,
G., F. Latif, F. M. Duh, R. Bernal, U. Smola, H. Li, I.
Kuzmin, V. Wixler, L. Geil, and S. Shrestha. 1996.
3pK, a new mitogen-activated protein kinase-activated protein kinase
located in the small cell lung cancer tumor suppressor gene region.Mol. Cell. Biol.
16:868-876.[Abstract]
- 187 Slentz-Kesler,
K., J. T. Moore, M. Lombard, J. Zhang, R. Hollingsworth, and
M. P. Weiner. 2000. Identification of the
human Mnk2 gene (MKNK2) through protein interaction with estrogen
receptor beta. Genomics
69:63-71.[CrossRef][Medline]
- 188 Smith,
J. A., C. E. Poteet-Smith, D. A.
Lannigan, T. A. Freed, A. J. Zoltoski, and
T. W. Sturgill. 2000. Creation of a
stress-activated p90 ribosomal S6 kinase. The carboxyl-terminal tail of
the MAPK-activated protein kinases dictates the signal
transduction pathway in which they function. J. Biol.
Chem.
275:31588-31593.[Abstract/Free Full Text]
- 189 Smith,
J. A., C. E. Poteet-Smith, K. Malarkey, and
T. W. Sturgill. 1999. Identification of an
extracellular signal-regulated kinase (ERK) docking site in ribosomal
S6 kinase, a sequence critical for activation by ERK in vivo.J. Biol. Chem.
274:2893-2898.[Abstract/Free Full Text]
- 190 Soloaga,
A., S. Thomson, G. R. Wiggin, N. Rampersaud, M. H.
Dyson, C. A. Hazzalin, L. C. Mahadevan, and
J. S. Arthur. 2003. MSK2 and MSK1 mediate
the mitogen- and stress-induced
phosphorylation of histone H3 and
HMG-14. EMBO J.
22:2788-2797.[CrossRef][Medline]
- 191 Sonenberg,
N., and T. E. Dever. 2003. Eukaryotic
translation initiation factors and regulators. Curr. Opin.
Struct. Biol.
13:56-63.[CrossRef][Medline]
- 192 Stokoe,
D., D. G. Campbell, S. Nakielny, H. Hidaka, S. J.
Leevers, C. Marshall, and P. Cohen. 1992.
MAPKAP kinase-2; a novel protein kinase activated by
mitogen-activated protein kinase. EMBO J.
11:3985-3994.[Medline]
- 193 Stokoe,
D., B. Caudwell, P. T. Cohen, and P. Cohen.1993
. The substrate specificity and structure of
mitogen-activated protein (MAP) kinase-activated protein kinase-2.Biochem. J.
296:843-849.[Medline]
- 194 Stokoe,
D., K. Engel, D. G. Campbell, P. Cohen, and M. Gaestel.1992
. Identification of MAPKAP kinase 2 as a
major enzyme responsible for the
phosphorylation of the small
mammalian heat shock proteins. FEBS Lett.
313:307-313.[CrossRef][Medline]
- 195 Sutherland,
C., J. Alterio, D. G. Campbell, B. Le Bourdelles, J. Mallet,
J. Haavik, and P. Cohen. 1993. Phosphorylation
and activation of human tyrosine hydroxylase in vitro by
mitogen-activated protein (MAP) kinase and MAP-kinase-activated kinases
1 and 2. Eur. J. Biochem.
217:715-722.[Abstract]
- 196 Sutherland,
C., I. A. Leighton, and P. Cohen. 1993.
Inactivation of glycogen synthase kinase-3 beta by
phosphorylation: new kinase
connections in insulin and growth-factor signalling. Biochem.
J.
296:15-19.[Medline]
- 197 Takahashi,
E., J. Abe, and B. C. Berk. 1997.
Angiotensin II stimulates p90rsk in vascular smooth muscle cells. A
potential Na+-H+ exchanger
kinase. Circ. Res.
81:268-273.[Abstract/Free Full Text]
- 198 Takahashi,
E., J. Abe, B. Gallis, R. Aebersold, D. J. Spring,
E. G. Krebs, and B. C. Berk. 1999.
p90(RSK) is a serum-stimulated Na+/H+ exchanger
isoform-1 kinase. Regulatory
phosphorylation of serine 703 of
Na+/H+ exchanger isoform-1. J. Biol.
Chem.
274:20206-20214.[Abstract/Free Full Text]
- 199 Tan,
Y., J. Rouse, A. Zhang, S. Cariati, P. Cohen, and M. J.
Comb. 1996. FGF and stress regulate CREB and ATF-1 via
a pathway involving p38 MAP kinase and MAPKAP kinase-2.EMBO J.
15:4629-4642.[Medline]
- 200 Tanoue,
T., M. Adachi, T. Moriguchi, and E. Nishida. 2000. A
conserved docking motif in MAP kinases common to substrates, activators
and regulators. Nat. Cell Biol.
2:110-116.[CrossRef][Medline]
- 201 Tanoue,
T., R. Maeda, M. Adachi, and E. Nishida. 2001.
Identification of a docking groove on ERK and p38 MAP kinases that
regulates the specificity of docking interactions. EMBO
J.
20:466-479.[CrossRef][Medline]
- 202 Tanoue,
T., and E. Nishida. 2003. Molecular recognitions in
the MAP kinase cascades. Cell Signal.
15:455-462.[CrossRef][Medline]
- 203 Tee,
A. R., D. C. Fingar, B. D. Manning,
D. J. Kwiatkowski, L. C. Cantley, and J.
Blenis. 2002. Tuberous sclerosis complex-1 and -2 gene
products function together to inhibit mammalian target of rapamycin
(mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci.
USA
99:13571-13576.[Abstract/Free Full Text]
- 204 Thomson,
S., A. L. Clayton, C. A. Hazzalin, S. Rose,
M. J. Barratt, and L. C. Mahadevan.1999
. The nucleosomal response associated with
immediate-early gene induction is mediated via alternative MAP kinase
cascades: MSK1 as a potential histone H3/HMG-14 kinase. EMBO
J.
18:4779-4793.[CrossRef][Medline]
- 205 Thomson,
S., L. C. Mahadevan, and A. L. Clayton.1999
. MAP kinase-mediated signalling to nucleosomes and
immediate-early gene induction. Semin. Cell Dev. Biol.
10:205-214.[CrossRef][Medline]
- 206 Toker,
A., and A. C. Newton. 2000. Akt/protein
kinase B is regulated by
autophosphorylation at the
hypothetical PDK-2 site. J. Biol. Chem.
275:8271-8274.[Abstract/Free Full Text]
- 207 Tomas-Zuber,
M., J. L. Mary, F. Lamour, D. Bur, and W. Lesslauer.2001
. C-terminal elements control location, activation
threshold, and p38 docking of ribosomal S6 kinase B (RSKB).J. Biol. Chem.
276:5892-5899.[Abstract/Free Full Text]
- 208 Tomas-Zuber,
M., J. L. Mary, and W. Lesslauer. 2000.
Control sites of ribosomal S6 kinase B and persistent activation
through tumor necrosis factor. J. Biol. Chem.
275:23549-23558.[Abstract/Free Full Text]
- 209 Tran,
H., F. Maurer, and Y. Nagamine. 2003.Stabilization of urokinase and urokinase receptor mRNAs
by HuR is linked to its cytoplasmic accumulation induced by activated
mitogen-activated protein kinase-activated protein kinase 2. Mol. Cell.
Biol.
23:7177-7188.
- 210 Trivier,
E., D. De Cesare, S. Jacquot, S. Pannetier, E. Zackai, I. Young,
J. L. Mandel, P. Sassone-Corsi, and A. Hanauer.1996
. Mutations in the kinase Rsk-2 associated with
Coffin-Lowry syndrome. Nature
384:567-570.[CrossRef][Medline]
- 211 Tunquist,
B. J., M. S. Schwab, L. G. Chen, and
J. L. Maller. 2002. The spindle checkpoint
kinase bub1 and cyclin e/cdk2 both contribute to the establishment of
meiotic metaphase arrest by cytostatic factor. Curr.
Biol.
12:1027-1033.[CrossRef][Medline]
- 212 Vadlamudi,
R. K., F. Li, L. Adam, D. Nguyen, Y. Ohta, T. P.
Stossel, and R. Kumar. 2002. Filamin is
essential in actin cytoskeletal assembly mediated by p21-activated
kinase 1. Nat. Cell Biol.
4:681-690.[CrossRef][Medline]
- 213 Vaidyanathan,
H., and J. W. Ramos. 2003. RSK2 activity is
regulated by its interaction with PEA-15. J. Biol.
Chem.
278:32367-32372.[Abstract/Free Full Text]
- 214 van
Hemert, M. J., H. Y. Steensma, and G. P.
van Heusden. 2001. 14-3-3 proteins:
key regulators of cell division, signalling and
apoptosis. Bioessays
23:936-946.[CrossRef][Medline]
- 215 Vasudevan,
S., and S. W. Peltz. 2001. Regulated
ARE-mediated mRNA decay in Saccharomyces cerevisiae.Mol. Cell
7:1191-1200.[CrossRef][Medline]
- 216 Vermeulen,
L., G. De Wilde, P. Van Damme, W. Vanden Berghe, and G. Haegeman.2003
. Transcriptional activation of the NF-kappaB p65
subunit by mitogen- and stress-activated protein kinase-1 (MSK1).EMBO J.
22:1313-1324.[CrossRef][Medline]
- 217 Vik,
T. A., and J. W. Ryder. 1997.
Identification of serine 380 as the major site of
autophosphorylation of
Xenopus pp90rsk. Biochem. Biophys. Res. Commun.
235:398-402.[CrossRef][Medline]
- 218 Wang,
X., L. Xu, H. Wang, P. R. Young, M. Gaestel, and G.
Z. Feuerstein. 2002. Mitogen-activated protein
kinase-activated protein (MAPKAP) kinase 2 deficiency protects
brain from ischemic injury in mice. J. Biol.
Chem.
277:43968-43972.[Abstract/Free Full Text]
- 219 Wang,
Z., P. C. Harkins, R. J. Ulevitch, J. Han,
M. H. Cobb, and E. J. Goldsmith.1997
. The structure of mitogen-activated protein
kinase p38 at 2.1-A resolution. Proc. Natl. Acad. Sci. USA
94:2327-2332.[Abstract/Free Full Text]
- 220 Wang,
Z., B. Zhang, M. Wang, and B. I. Carr. 2003.
Persistent ERK phosphorylation
negatively regulates cAMP response element-binding protein (CREB)
activity via recruitment of CREB-binding protein to pp90RSK.J. Biol. Chem.
278:11138-11144.[Abstract/Free Full Text]
- 221 Waskiewicz,
A. J., A. Flynn, C. G. Proud, and J. A.
Cooper. 1997. Mitogen-activated protein kinases
activate the serine/threonine kinases Mnk1 and Mnk2. EMBO
J.
16:1909-1920.[CrossRef][Medline]
- 222 Waskiewicz,
A. J., J. C. Johnson, B. Penn, M. Mahalingam,
S. R. Kimball, and J. A. Cooper.1999
. Phosphorylation of the cap-binding protein
eukaryotic translation initiation factor 4E by protein kinase Mnk1 in
vivo. Mol. Cell. Biol.
19:1871-1880.[Abstract/Free Full Text]
- 223 Wassarman,
D. A., N. M. Solomon, and G. M.
Rubin. 1994. The Drosophila melanogaster ribosomal S6
kinase II-encoding sequence. Gene
144:309-310.[CrossRef][Medline]
- 224 Werz,
O., J. Klemm, B. Samuelsson, and O. Radmark. 2000.
5-lipoxygenase is phosphorylated by
p38 kinase-dependent MAPKAP kinases. Proc. Natl. Acad.
Sci. USA
97:5261-5266.[Abstract/Free Full Text]
- 225 Weston,
C. R., and R. J. Davis. 2002. The
JNK signal transduction pathway. Curr. Opin. Genet. Dev.
12:14-21.[CrossRef][Medline]
- 226 Whitmarsh,
A. J., and R. J. Davis. 1998.
Structural organization of MAP-kinase signaling modules by scaffold
proteins in yeast and mammals. Trends Biochem. Sci.
23:481-485.[CrossRef][Medline]
- 227 Wierenga,
A. T., I. Vogelzang, B. J. Eggen, and E.
Vellenga. 2003. Erythropoietin-induced serine 727
phosphorylation of STAT3 in
erythroid cells is mediated by a MEK-, ERK-, and MSK1-dependent
pathway. Exp. Hematol.
31:398-405.[CrossRef][Medline]
- 228 Wiggin,
G. R., A. Soloaga, J. M. Foster, V. Murray-Tait, P.
Cohen, and J. S. Arthur. 2002. MSK1 and MSK2
are required for the mitogen- and stress-induced
phosphorylation of CREB and ATF1 in
fibroblasts. Mol. Cell. Biol.
22:2871-2881.[Abstract/Free Full Text]
- 229 Williams,
M. R., J. S. Arthur, A. Balendran, J. van der Kaay,
V. Poli, P. Cohen, and D. R. Alessi. 2000.
The role of 3-phosphoinositide-dependent protein kinase 1 in activating
AGC kinases defined in embryonic stem cells. Curr. Biol.
10:439-448.[CrossRef][Medline]
- 230 Wilson,
K. P., M. J. Fitzgibbon, P. R. Caron,
J. P. Griffith, W. Chen, P. G. McCaffrey,
S. P. Chambers, and M. S. Su.1996
. Crystal structure of p38 mitogen-activated protein
kinase. J. Biol. Chem.
271:27696-27700.[Abstract/Free Full Text]
- 231 Winzen,
R., M. Kracht, B. Ritter, A. Wilhelm, C. Y. Chen,
A. B. Shyu, M. Muller, M. Gaestel, K. Resch, and H.
Holtmann. 1999. The p38 MAP kinase pathway signals for
cytokine-induced mRNA stabilization via MAP kinase-activated
protein kinase 2 and an AU-rich region-targeted mechanism. EMBO
J.
18:4969-4980.[CrossRef][Medline]
- 232 Wong,
E. V., A. W. Schaefer, G. Landreth, and V.
Lemmon. 1996. Involvement of p90rsk in neurite
outgrowth mediated by the cell adhesion molecule L1.J. Biol. Chem.
271:18217-18223.[Abstract/Free Full Text]
- 233 Woo,
M. S., Y. Ohta, I. Rabinovitz, T. P. Stossel, and
J. Blenis. 2004. Ribosomal S6 kinase regulates
phosphorylation of filamin A on an
important regulatory site. Mol. Cell. Biol.
24:3025-3035.[Abstract/Free Full Text]
- 234 Wood,
K., C. Sarnecki, T. M. Roberts, and J. Blenis.1992
. c-Ras mediates nerve growth factor receptor
modulation of three signal-transducing protein kinases: MAP kinase,
Raf-1 and RSK. Cell
68:1041-1050.[CrossRef][Medline]
- 235 Wright,
J. H., E. Munar, D. R. Jameson, P. R.
Andreassen, R. L. Margolis, R. Seger, and E. G.
Krebs. 1999. Mitogen-activated protein kinase kinase
activity is required for the G2/M transition of the cell
cycle in mammalian fibroblasts. Proc. Natl. Acad. Sci.
USA
96:11335-11340.[Abstract/Free Full Text]
- 236 Wu,
J., and R. Janknecht. 2002. Regulation of the
ETS transcription factor ER81 by the 90-kDa ribosomal S6 kinase 1 and
protein kinase A. J. Biol. Chem.
277:42669-42679.[Abstract/Free Full Text]
- 237 Wu,
M., T. J. Hemesath, C. M. Takemoto, M. A.
Horstmann, A. G. Wells, E. R. Price, D.
Z. Fisher, and D. E. Fisher. 2000. c-Kit
triggers dual phosphorylations,
which couple activation and degradation of the essential melanocyte
factor Mi. Genes Dev.
14:301-312.[Abstract/Free Full Text]
- 238 Xia,
Y., C. Makris, B. Su, E. Li, J. Yang, G. R. Nemerow, and M.
Karin. 2000. MEK kinase 1 is critically required for
c-Jun N-terminal kinase activation by proinflammatory stimuli and
growth factor-induced cell migration. Proc. Natl. Acad. Sci.
USA
97:5243-5248.[Abstract/Free Full Text]
- 239 Xing,
J., D. D. Ginty, and M. E. Greenberg.1996
. Coupling of the RAS-MAPK pathway to gene
activation by RSK2, a growth factor-regulated CREB kinase.Science
273:959-963.[Abstract]
- 240 Yaffe,
M. B. 2002. How do 14-3-3
proteins work?Gatekeeper
phosphorylation and the molecular
anvil hypothesis. FEBS Lett.
513:53-57.[CrossRef][Medline]
- 241 Yntema,
H. G., B. van den Helm, J. Kissing, G. van Duijnhoven, F.
Poppelaars, J. Chelly, C. Moraine, J. P. Fryns,
B. C. Hamel, H. Heilbronner, H. J. Pander,
H. G. Brunner, H. H. Ropers, F. P.
Cremers, and H. van Bokhoven. 1999. A novel ribosomal
S6-kinase (RSK4; RPS6KA6) is commonly deleted in patients with complex
X-linked mental retardation. Genomics
62:332-343.[CrossRef][Medline]
- 242 Yujiri,
T., S. Sather, G. R. Fanger, and G. L. Johnson.1998
. Role of MEKK1 in cell survival and activation of JNK
and ERK pathways defined by targeted gene disruption.Science
282:1911-1914.[Abstract/Free Full Text]
- 243 Zeniou,
M., T. Ding, E. Trivier, and A. Hanauer. 2002.
Expression analysis of RSK gene family members: the RSK2 gene, mutated
in Coffin-Lowry syndrome, is prominently expressed in brain structures
essential for cognitive function and learning. Hum. Mol.
Genet.
11:2929-2940.[Abstract/Free Full Text]
- 244 Zhang,
Y., G. Liu, and Z. Dong. 2001. MSK1 and JNKs mediate
phosphorylation of STAT3 in
UVA-irradiated mouse epidermal JB6 cells. J. Biol.
Chem.
276:42534-42542.[Abstract/Free Full Text]
- 245 Zhao,
J., X. Yuan, M. Frodin, and I. Grummt. 2003.
ERK-dependent phosphorylation of
the transcription initiation factor TIF-IA is required for RNA
polymerase I transcription and cell growth. Mol. Cell
11:405-413.[CrossRef][Medline]
- 246 Zhao,
Y., C. Bjorbaek, and D. E. Moller. 1996.
Regulation and interaction of pp90rsk isoforms with
mitogen-activated protein kinases. J. Biol.
Chem.
271:29773-29779.[Abstract/Free Full Text]
- 247 Zhao,
Y., C. Bjorbaek, S. Weremowicz, C. C. Morton, and
D. E. Moller. 1995. RSK3 encodes a novel
pp90rsk isoform with a unique N-terminal sequence: growth
factor-stimulated kinase function and nuclear translocation.Mol. Cell. Biol.
15:4353-4363.[Abstract]
- 248 Zhu,
S., and D. S. Gerhard. 1998. A transcript
map of an 800-kb region on human chromosome 11q13, part of the
candidate region for SCA5 and BBS1. Hum. Genet.
103:674-680.[CrossRef][Medline]
- 249 Zu,
Y. L., F. Wu, A. Gilchrist, Y. Ai, M. E. Labadia,
and C. K. Huang. 1994. The primary
structure of a human MAP kinase activated protein kinase 2. Biochem.
Biophys. Res. Commun.
200:1118-1124.[CrossRef][Medline]
Microbiology and Molecular Biology Reviews, June 2004, p. 320-344, Vol. 68, No. 2
1092-2172/04/$08.00+0 DOI: 10.1128/MMBR.68.2.320-344.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Asur, R., Balasubramaniam, M., Marples, B., Thomas, R. A., Tucker, J. D.
(2010). Bystander effects induced by chemicals and ionizing radiation: evaluation of changes in gene expression of downstream MAPK targets. Mutagenesis
: geq003v1-geq003
[Abstract]
[Full Text]
-
Chang, Y.-M., Shih, Y.-T., Chen, Y.-S., Liu, C.-L., Fang, W.-K., Tsai, C.-H., Tsai, F.-J., Kuo, W.-W., Lai, T.-Y., Huang, C.-Y.
(2010). Schwann Cell Migration Induced by Earthworm Extract via Activation of PAs and MMP2/9 Mediated through ERK1/2 and p38. Evid Based Complement Alternat Med
: nep131v2-nep131
[Abstract]
[Full Text]
-
Busa, R., Geremia, R., Sette, C.
(2010). Genotoxic stress causes the accumulation of the splicing regulator Sam68 in nuclear foci of transcriptionally active chromatin. Nucleic Acids Res
: gkq004v1-gkq004
[Abstract]
[Full Text]
-
Jacks, K. A., Koch, C. A.
(2010). Differential Regulation of Mitogen- and Stress-activated Protein Kinase-1 and -2 (MSK1 and MSK2) by CK2 following UV Radiation. J. Biol. Chem.
285: 1661-1670
[Abstract]
[Full Text]
-
Shi, Z.-D., Ji, X.-Y., Berardi, D. E., Qazi, H., Tarbell, J. M.
(2010). Interstitial flow induces MMP-1 expression and vascular SMC migration in collagen I gels via an ERK1/2-dependent and c-Jun-mediated mechanism. Am. J. Physiol. Heart Circ. Physiol.
298: H127-H135
[Abstract]
[Full Text]
-
Chen, H., Zhu, G., Li, Y., Padia, R. N., Dong, Z., Pan, Z. K., Liu, K., Huang, S.
(2009). Extracellular Signal-Regulated Kinase Signaling Pathway Regulates Breast Cancer Cell Migration by Maintaining slug Expression. Cancer Res.
69: 9228-9235
[Abstract]
[Full Text]
-
Beck, I. M. E., Vanden Berghe, W., Vermeulen, L., Yamamoto, K. R., Haegeman, G., De Bosscher, K.
(2009). Crosstalk in Inflammation: The Interplay of Glucocorticoid Receptor-Based Mechanisms and Kinases and Phosphatases. Endocr. Rev.
30: 830-882
[Abstract]
[Full Text]
-
Piette, C., Deprez, M., Roger, T., Noel, A., Foidart, J.-M., Munaut, C.
(2009). The Dexamethasone-induced Inhibition of Proliferation, Migration, and Invasion in Glioma Cell Lines Is Antagonized by Macrophage Migration Inhibitory Factor (MIF) and Can Be Enhanced by Specific MIF Inhibitors. J. Biol. Chem.
284: 32483-32492
[Abstract]
[Full Text]
-
Clayton, C. C., Xu, M., Chavkin, C.
(2009). Tyrosine Phosphorylation of Kir3 following {kappa}-Opioid Receptor Activation of p38 MAPK Causes Heterologous Desensitization. J. Biol. Chem.
284: 31872-31881
[Abstract]
[Full Text]
-
Guy, G R, Jackson, R A, Yusoff, P, Chow, S Y
(2009). Sprouty proteins: modified modulators, matchmakers or missing links?. J Endocrinol
203: 191-202
[Abstract]
[Full Text]
-
O'Mahony, F., Alzamora, R., Chung, H.-L., Thomas, W., Harvey, B. J.
(2009). Genomic Priming of the Antisecretory Response to Estrogen in Rat Distal Colon throughout the Estrous Cycle. Mol. Endocrinol.
23: 1885-1899
[Abstract]
[Full Text]
-
Sixt, M.-L., Messlinger, K., Fischer, M. J. M.
(2009). Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigeminal nucleus. Brain
132: 3134-3141
[Abstract]
[Full Text]
-
Belfiore, A., Frasca, F., Pandini, G., Sciacca, L., Vigneri, R.
(2009). Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease. Endocr. Rev.
30: 586-623
[Abstract]
[Full Text]
-
Rodriguez-Garcia, M. E., Quiroga, A. G., Castro, J., Ortiz, A., Aller, P., Mata, F.
(2009). Inhibition of p38-MAPK Potentiates Cisplatin-Induced Apoptosis via GSH Depletion and Increases Intracellular Drug Accumulation in Growth-Arrested Kidney Tubular Epithelial Cells. Toxicol Sci
111: 413-423
[Abstract]
[Full Text]
-
Thandavarayan, R. A., Watanabe, K., Ma, M., Gurusamy, N., Veeraveedu, P. T., Konishi, T., Zhang, S., Muslin, A. J., Kodama, M., Aizawa, Y.
(2009). Dominant-negative p38{alpha} mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus. Am. J. Physiol. Heart Circ. Physiol.
297: H911-H919
[Abstract]
[Full Text]
-
Ansari, H. R., Teng, B., Nadeem, A., Roush, K. P., Martin, K. H., Schnermann, J., Mustafa, S. J.
(2009). A1 adenosine receptor-mediated PKC and p42/p44 MAPK signaling in mouse coronary artery smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol.
297: H1032-H1039
[Abstract]
[Full Text]
-
Malik, A. I., Storey, K. B.
(2009). Activation of extracellular signal-regulated kinases during dehydration in the African clawed frog, Xenopus laevis. J. Exp. Biol.
212: 2595-2603
[Abstract]
[Full Text]
-
Periyasamy-Thandavan, S., Jiang, M., Schoenlein, P., Dong, Z.
(2009). Autophagy: molecular machinery, regulation, and implications for renal pathophysiology. Am. J. Physiol. Renal Physiol.
297: F244-F256
[Abstract]
[Full Text]
-
Bajbouj, K., Poehlmann, A., Kuester, D., Drewes, T., Haase, K., Hartig, R., Teller, A., Kliche, S., Walluscheck, D., Ivanovska, J., Chakilam, S., Ulitzsch, A., Bommhardt, U., Leverkus, M., Roessner, A., Schneider-Stock, R.
(2009). Identification of Phosphorylated p38 as a Novel DAPK-Interacting Partner during TNF{alpha}-Induced Apoptosis in Colorectal Tumor Cells. Am. J. Pathol.
175: 557-570
[Abstract]
[Full Text]
-
Aberg, E., Torgersen, K. M., Johansen, B., Keyse, S. M., Perander, M., Seternes, O.-M.
(2009). Docking of PRAK/MK5 to the Atypical MAPKs ERK3 and ERK4 Defines a Novel MAPK Interaction Motif. J. Biol. Chem.
284: 19392-19401
[Abstract]
[Full Text]
-
Larrea, M. D., Hong, F., Wander, S. A., da Silva, T. G., Helfman, D., Lannigan, D., Smith, J. A., Slingerland, J. M.
(2009). RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proc. Natl. Acad. Sci. USA
106: 9268-9273
[Abstract]
[Full Text]
-
Mittelstadt, P. R., Yamaguchi, H., Appella, E., Ashwell, J. D.
(2009). T Cell Receptor-mediated Activation of p38{alpha} by Mono-phosphorylation of the Activation Loop Results in Altered Substrate Specificity. J. Biol. Chem.
284: 15469-15474
[Abstract]
[Full Text]
-
Sagou, K., Imai, T., Sagara, H., Uema, M., Kawaguchi, Y.
(2009). Regulation of the Catalytic Activity of Herpes Simplex Virus 1 Protein Kinase Us3 by Autophosphorylation and Its Role in Pathogenesis. J. Virol.
83: 5773-5783
[Abstract]
[Full Text]
-
Tamizhselvi, R., Sun, J., Koh, Y.-H., Bhatia, M.
(2009). Effect of Hydrogen Sulfide on the Phosphatidylinositol 3-Kinase-Protein Kinase B Pathway and on Caerulein-Induced Cytokine Production in Isolated Mouse Pancreatic Acinar Cells. J. Pharmacol. Exp. Ther.
329: 1166-1177
[Abstract]
[Full Text]
-
Kuang, E., Wu, F., Zhu, F.
(2009). Mechanism of Sustained Activation of Ribosomal S6 Kinase (RSK) and ERK by Kaposi Sarcoma-associated Herpesvirus ORF45: MULTIPROTEIN COMPLEXES RETAIN ACTIVE PHOSPHORYLATED ERK AND RSK AND PROTECT THEM FROM DEPHOSPHORYLATION. J. Biol. Chem.
284: 13958-13968
[Abstract]
[Full Text]
-
Cho, Y.-Y., Yao, K., Pugliese, A., Malakhova, M. L., Bode, A. M., Dong, Z.
(2009). A Regulatory Mechanism for RSK2 NH2-Terminal Kinase Activity. Cancer Res.
69: 4398-4406
[Abstract]
[Full Text]
-
Mikkelsen, S. S., Jensen, S. B., Chiliveru, S., Melchjorsen, J., Julkunen, I., Gaestel, M., Arthur, J. S. C., Flavell, R. A., Ghosh, S., Paludan, S. R.
(2009). RIG-I-mediated Activation of p38 MAPK Is Essential for Viral Induction of Interferon and Activation of Dendritic Cells: DEPENDENCE ON TRAF2 AND TAK1. J. Biol. Chem.
284: 10774-10782
[Abstract]
[Full Text]
-
Kakugawa, S., Shimojima, M., Goto, H., Horimoto, T., Oshimori, N., Neumann, G., Yamamoto, T., Kawaoka, Y.
(2009). Mitogen-Activated Protein Kinase-Activated Kinase RSK2 Plays a Role in Innate Immune Responses to Influenza Virus Infection. J. Virol.
83: 2510-2517
[Abstract]
[Full Text]
-
Gharib, M., Marcantonio, M., Lehmann, S. G., Courcelles, M., Meloche, S., Verreault, A., Thibault, P.
(2009). Artifactual Sulfation of Silver-stained Proteins: Implications for the Assignment of Phosphorylation and Sulfation Sites. Mol. Cell. Proteomics
8: 506-518
[Abstract]
[Full Text]
-
Gillis, P. A., Okagaki, L. H., Rice, S. A.
(2009). Herpes Simplex Virus Type 1 ICP27 Induces p38 Mitogen-Activated Protein Kinase Signaling and Apoptosis in HeLa Cells. J. Virol.
83: 1767-1777
[Abstract]
[Full Text]
-
Sanchez-Nino, M. D., Sanz, A. B., Ihalmo, P., Lassila, M., Holthofer, H., Mezzano, S., Aros, C., Groop, P.-H., Saleem, M. A., Mathieson, P. W., Langham, R., Kretzler, M., Nair, V., Lemley, K. V., Nelson, R. G., Mervaala, E., Mattinzoli, D., Rastaldi, M. P., Ruiz-Ortega, M., Martin-Ventura, J. L., Egido, J., Ortiz, A.
(2009). The MIF Receptor CD74 in Diabetic Podocyte Injury. J. Am. Soc. Nephrol.
20: 353-362
[Abstract]
[Full Text]
-
Garcia, P., Tajadura, V., Sanchez, Y.
(2009). The Rho1p Exchange Factor Rgf1p Signals Upstream from the Pmk1 Mitogen-activated Protein Kinase Pathway in Fission Yeast. Mol. Biol. Cell
20: 721-731
[Abstract]
[Full Text]
-
Chiloeches, A., Sanchez-Pacheco, A., Gil-Araujo, B., Aranda, A., Lasa, M.
(2008). Thyroid Hormone-Mediated Activation of the ERK/Dual Specificity Phosphatase 1 Pathway Augments the Apoptosis of GH4C1 Cells by Down-Regulating Nuclear Factor-{kappa}B Activity. Mol. Endocrinol.
22: 2466-2480
[Abstract]
[Full Text]
-
Kim, M.-J., Choi, S.-Y., Park, I.-C., Hwang, S.-G., Kim, C., Choi, Y.-H., Kim, H., Lee, K.-H., Lee, S.-J.
(2008). Opposing Roles of c-Jun NH2-Terminal Kinase and p38 Mitogen-Activated Protein Kinase in the Cellular Response to Ionizing Radiation in Human Cervical Cancer Cells. Mol Cancer Res
6: 1718-1731
[Abstract]
[Full Text]
-
Zhang, Y.-Y., Mei, Z.-Q., Wu, J.-W., Wang, Z.-X.
(2008). Enzymatic Activity and Substrate Specificity of Mitogen-activated Protein Kinase p38{alpha} in Different Phosphorylation States. J. Biol. Chem.
283: 26591-26601
[Abstract]
[Full Text]
-
Naidu, S., Wijayanti, N., Santoso, S., Kietzmann, T., Immenschuh, S.
(2008). An Atypical NF-{kappa}B-Regulated Pathway Mediates Phorbol Ester-Dependent Heme Oxygenase-1 Gene Activation in Monocytes. J. Immunol.
181: 4113-4123
[Abstract]
[Full Text]
-
Murk, W., Atabekoglu, C. S., Cakmak, H., Heper, A., Ensari, A., Kayisli, U. A., Arici, A.
(2008). Extracellularly Signal-Regulated Kinase Activity in the Human Endometrium: Possible Roles in the Pathogenesis of Endometriosis. J. Clin. Endocrinol. Metab.
93: 3532-3540
[Abstract]
[Full Text]
-
Reijerkerk, A., Kooij, G., van der Pol, S. M. A., Leyen, T., van het Hof, B., Couraud, P.-O., Vivien, D., Dijkstra, C. D., de Vries, H. E.
(2008). Tissue-Type Plasminogen Activator Is a Regulator of Monocyte Diapedesis through the Brain Endothelial Barrier. J. Immunol.
181: 3567-3574
[Abstract]
[Full Text]
-
Sun, J., Ramnath, R. D., Tamizhselvi, R., Bhatia, M.
(2008). Neurokinin A engages neurokinin-1 receptor to induce NF-{kappa}B-dependent gene expression in murine macrophages: implications of ERK1/2 and PI 3-kinase/Akt pathways. Am. J. Physiol. Cell Physiol.
295: C679-C691
[Abstract]
[Full Text]
-
Hussain, T., Nasreen, N., Lai, Y., Bellew, B. F., Antony, V. B., Mohammed, K. A.
(2008). Innate immune responses in murine pleural mesothelial cells: Toll-like receptor-2 dependent induction of {beta}-defensin-2 by staphylococcal peptidoglycan. Am. J. Physiol. Lung Cell. Mol. Physiol.
295: L461-L470
[Abstract]
[Full Text]
-
Ren, J.-G., Li, Z., Sacks, D. B.
(2008). IQGAP1 Integrates Ca2+/Calmodulin and B-Raf Signaling. J. Biol. Chem.
283: 22972-22982
[Abstract]
[Full Text]
-
Proctor, B. M., Jin, X., Lupu, T. S., Muglia, L. J., Semenkovich, C. F., Muslin, A. J.
(2008). Requirement for p38 Mitogen-Activated Protein Kinase Activity in Neointima Formation After Vascular Injury. Circulation
118: 658-666
[Abstract]
[Full Text]
-
Zhang, Y., Bai, X.-T., Zhu, K.-Y., Jin, Y., Deng, M., Le, H.-Y., Fu, Y.-F., Chen, Y., Zhu, J., Look, A. T., Kanki, J., Chen, Z., Chen, S.-J., Liu, T. X.
(2008). In Vivo Interstitial Migration of Primitive Macrophages Mediated by JNK-Matrix Metalloproteinase 13 Signaling in Response to Acute Injury. J. Immunol.
181: 2155-2164
[Abstract]
[Full Text]
-
Kuwano, Y., Kim, H. H., Abdelmohsen, K., Pullmann, R. Jr., Martindale, J. L., Yang, X., Gorospe, M.
(2008). MKP-1 mRNA Stabilization and Translational Control by RNA-Binding Proteins HuR and NF90. Mol. Cell. Biol.
28: 4562-4575
[Abstract]
[Full Text]
-
Kato, A., Tanaka, M., Yamamoto, M., Asai, R., Sata, T., Nishiyama, Y., Kawaguchi, Y.
(2008). Identification of a Physiological Phosphorylation Site of the Herpes Simplex Virus 1-Encoded Protein Kinase Us3 Which Regulates Its Optimal Catalytic Activity In Vitro and Influences Its Function in Infected Cells. J. Virol.
82: 6172-6189
[Abstract]
[Full Text]
-
Sorensen, V., Zhen, Y., Zakrzewska, M., Haugsten, E. M., Walchli, S., Nilsen, T., Olsnes, S., Wiedlocha, A.
(2008). Phosphorylation of Fibroblast Growth Factor (FGF) Receptor 1 at Ser777 by p38 Mitogen-Activated Protein Kinase Regulates Translocation of Exogenous FGF1 to the Cytosol and Nucleus. Mol. Cell. Biol.
28: 4129-4141
[Abstract]
[Full Text]
-
Mokhtari, D., Myers, J. W., Welsh, N.
(2008). The MAPK Kinase Kinase-1 Is Essential for Stress-Induced Pancreatic Islet Cell Death. Endocrinology
149: 3046-3053
[Abstract]
[Full Text]
-
Rodriguez, M., Kim, B., Lee, N.-S., Veeranki, S., Kim, L.
(2008). MPL1, a Novel Phosphatase with Leucine-Rich Repeats, Is Essential for Proper ERK2 Phosphorylation and Cell Motility. Eukaryot Cell
7: 958-966
[Abstract]
[Full Text]
-
Sun, J., Ramnath, R. D., Zhi, L., Tamizhselvi, R., Bhatia, M.
(2008). Substance P enhances NF-{kappa}B transactivation and chemokine response in murine macrophages via ERK1/2 and p38 MAPK signaling pathways. Am. J. Physiol. Cell Physiol.
294: C1586-C1596
[Abstract]
[Full Text]
-
Lerner-Marmarosh, N., Miralem, T., Gibbs, P. E. M., Maines, M. D.
(2008). Human biliverdin reductase is an ERK activator; hBVR is an ERK nuclear transporter and is required for MAPK signaling. Proc. Natl. Acad. Sci. USA
105: 6870-6875
[Abstract]
[Full Text]
-
Sethu, S., Mendez-Corao, G., Melendez, A. J.
(2008). Phospholipase D1 Plays a Key Role in TNF-{alpha} Signaling. J. Immunol.
180: 6027-6034
[Abstract]
[Full Text]
-
Voong, L. N., Slater, A. R., Kratovac, S., Cressman, D. E.
(2008). Mitogen-activated Protein Kinase ERK1/2 Regulates the Class II Transactivator. J. Biol. Chem.
283: 9031-9039
[Abstract]
[Full Text]
-
Morrison, P. J., Hara, D., Ding, Z., Ivy, J. L.
(2008). Adding protein to a carbohydrate supplement provided after endurance exercise enhances 4E-BP1 and RPS6 signaling in skeletal muscle. J. Appl. Physiol.
104: 1029-1036
[Abstract]
[Full Text]
-
Junttila, M. R., Li, S.-P., Westermarck, J.
(2008). Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J.
22: 954-965
[Abstract]
[Full Text]
-
Vyshemirsky, V., Girolami, M. A.
(2008). Bayesian ranking of biochemical system models. Bioinformatics
24: 833-839
[Abstract]
[Full Text]
-
Stanic, D., Paratcha, G., Ledda, F., Herzog, H., Kopin, A. S., Hokfelt, T.
(2008). Peptidergic influences on proliferation, migration, and placement of neural progenitors in the adult mouse forebrain. Proc. Natl. Acad. Sci. USA
105: 3610-3615
[Abstract]
[Full Text]
-
Wasylyk, C., Zheng, H., Castell, C., Debussche, L., Multon, M.-C., Wasylyk, B.
(2008). Inhibition of the Ras-Net (Elk-3) Pathway by a Novel Pyrazole that Affects Microtubules. Cancer Res.
68: 1275-1283
[Abstract]
[Full Text]
-
Kuang, E., Tang, Q., Maul, G. G., Zhu, F.
(2008). Activation of p90 Ribosomal S6 Kinase by ORF45 of Kaposi's Sarcoma-Associated Herpesvirus and Its Role in Viral Lytic Replication. J. Virol.
82: 1838-1850
[Abstract]
[Full Text]
-
Martin, M. C., Allan, L. A., Mancini, E. J., Clarke, P. R.
(2008). The Docking Interaction of Caspase-9 with ERK2 Provides a Mechanism for the Selective Inhibitory Phosphorylation of Caspase-9 at Threonine 125. J. Biol. Chem.
283: 3854-3865
[Abstract]
[Full Text]
-
Helikar, T., Konvalina, J., Heidel, J., Rogers, J. A.
(2008). Emergent decision-making in biological signal transduction networks. Proc. Natl. Acad. Sci. USA
105: 1913-1918
[Abstract]
[Full Text]
-
Dai, J.-Q., Zhu, X.-J., Liu, F.-Q., Xiang, J.-H., Nagasawa, H., Yang, W.-J.
(2008). Involvement of p90 Ribosomal S6 Kinase in Termination of Cell Cycle Arrest during Development of Artemia-encysted Embryos. J. Biol. Chem.
283: 1705-1712
[Abstract]
[Full Text]
-
Eckstein, N., Servan, K., Girard, L., Cai, D., von Jonquieres, G., Jaehde, U., Kassack, M. U., Gazdar, A. F., Minna, J. D., Royer, H.-D.
(2008). Epidermal Growth Factor Receptor Pathway Analysis Identifies Amphiregulin as a Key Factor for Cisplatin Resistance of Human Breast Cancer Cells. J. Biol. Chem.
283: 739-750
[Abstract]
[Full Text]
-
Chen, D., Wilkinson, C. R.M., Watt, S., Penkett, C. J., Toone, W. M., Jones, N., Bahler, J.
(2008). Multiple Pathways Differentially Regulate Global Oxidative Stress Responses in Fission Yeast. Mol. Biol. Cell
19: 308-317
[Abstract]
[Full Text]
-
Gerits, N., Mikalsen, T., Kostenko, S., Shiryaev, A., Johannessen, M., Moens, U.
(2007). Modulation of F-actin Rearrangement by the Cyclic AMP/cAMP-dependent Protein Kinase (PKA) Pathway Is Mediated by MAPK-activated Protein Kinase 5 and Requires PKA-induced Nuclear Export of MK5. J. Biol. Chem.
282: 37232-37243
[Abstract]
[Full Text]
-
Zenkel, M., Kruse, F. E., Naumann, G. O. H., Schlotzer-Schrehardt, U.
(2007). Impaired Cytoprotective Mechanisms in Eyes with Pseudoexfoliation Syndrome/Glaucoma. IOVS
48: 5558-5566
[Abstract]
[Full Text]
-
Coss, D., Hand, C. M., Yaphockun, K. K. J., Ely, H. A., Mellon, P. L.
(2007). p38 Mitogen-Activated Protein Kinase Is Critical for Synergistic Induction of the FSH{beta} Gene by Gonadotropin-Releasing Hormone and Activin through Augmentation of c-Fos Induction and Smad Phosphorylation. Mol. Endocrinol.
21: 3071-3086
[Abstract]
[Full Text]
-
Rayalam, S., Della-Fera, M. A., Yang, J.-Y., Park, H. J., Ambati, S., Baile, C. A.
(2007). Resveratrol Potentiates Genistein's Antiadipogenic and Proapoptotic Effects in 3T3-L1 Adipocytes. J. Nutr.
137: 2668-2673
[Abstract]
[Full Text]
-
Patzak, A., Lai, E. Y., Fahling, M., Sendeski, M., Martinka, P., Persson, P. B., Persson, A. E. G.
(2007). Adenosine enhances long term the contractile response to angiotensin II in afferent arterioles. Am. J. Physiol. Regul. Integr. Comp. Physiol.
293: R2232-R2242
[Abstract]
[Full Text]
-
Madrid, M., Nunez, A., Soto, T., Vicente-Soler, J., Gacto, M., Cansado, J.
(2007). Stress-activated Protein Kinase-mediated Down-Regulation of the Cell Integrity Pathway Mitogen-activated Protein Kinase Pmk1p by Protein Phosphatases. Mol. Biol. Cell
18: 4405-4419
[Abstract]
[Full Text]
-
Amazit, L., Pasini, L., Szafran, A. T., Berno, V., Wu, R.-C., Mielke, M., Jones, E. D., Mancini, M. G., Hinojos, C. A., O'Malley, B. W., Mancini, M. A.
(2007). Regulation of SRC-3 Intercompartmental Dynamics by Estrogen Receptor and Phosphorylation. Mol. Cell. Biol.
27: 6913-6932
[Abstract]
[Full Text]
-
Kim, S.-W., Hong, J. S., Ryu, S.-H., Chung, W.-C., Yoon, J.-H., Koo, J. S.
(2007). Regulation of Mucin Gene Expression by CREB via a Nonclassical Retinoic Acid Signaling Pathway. Mol. Cell. Biol.
27: 6933-6947
[Abstract]
[Full Text]
-
James, B. P., Bunch, T. A., Krishnamoorthy, S., Perkins, L. A., Brower, D. L.
(2007). Nuclear Localization of the ERK MAP Kinase Mediated by Drosophila {alpha}PS2betaPS Integrin and Importin-7. Mol. Biol. Cell
18: 4190-4199
[Abstract]
[Full Text]
-
Wang, Y.
(2007). Mitogen-Activated Protein Kinases in Heart Development and Diseases. Circulation
116: 1413-1423
[Abstract]
[Full Text]
-
Chen, D., Reierstad, S., Lin, Z., Lu, M., Brooks, C., Li, N., Innes, J., Bulun, S. E.
(2007). Prostaglandin E2 Induces Breast Cancer Related Aromatase Promoters via Activation of p38 and c-Jun NH2-Terminal Kinase in Adipose Fibroblasts. Cancer Res.
67: 8914-8922
[Abstract]
[Full Text]
-
McKay, M. M., Morrison, D. K.
(2007). Caspase-dependent Cleavage Disrupts the ERK Cascade Scaffolding Function of KSR1. J. Biol. Chem.
282: 26225-26234
[Abstract]
[Full Text]
-
Cho, Y.-Y., Yao, K., Kim, H.-G., Kang, B. S., Zheng, D., Bode, A. M., Dong, Z.
(2007). Ribosomal S6 Kinase 2 Is a Key Regulator in Tumor Promoter Induced Cell Transformation. Cancer Res.
67: 8104-8112
[Abstract]
[Full Text]
-
Kunath, T., Saba-El-Leil, M. K., Almousailleakh, M., Wray, J., Meloche, S., Smith, A.
(2007). FGF stimulation of the Erk1/2 signalling cascade triggers transition of pluripotent embryonic stem cells from self-renewal to lineage commitment. Development
134: 2895-2902
[Abstract]
[Full Text]
-
Tesz, G. J., Guilherme, A., Guntur, K. V. P., Hubbard, A. C., Tang, X., Chawla, A., Czech, M. P.
(2007). Tumor Necrosis Factor {alpha} (TNF{alpha}) Stimulates Map4k4 Expression through TNF{alpha} Receptor 1 Signaling to c-Jun and Activating Transcription Factor 2. J. Biol. Chem.
282: 19302-19312
[Abstract]
[Full Text]
-
Kelley, M. J., Rose, A., Song, K., Lystrup, B., Samples, J. W., Acott, T. S.
(2007). p38 MAP Kinase Pathway and Stromelysin Regulation in Trabecular Meshwork Cells. IOVS
48: 3126-3137
[Abstract]
[Full Text]
-
Kramer, H. F., Goodyear, L. J.
(2007). Exercise, MAPK, and NF-{kappa}B signaling in skeletal muscle. J. Appl. Physiol.
103: 388-395
[Abstract]
[Full Text]
-
Ren, J.-G., Li, Z., Sacks, D. B.
(2007). IQGAP1 modulates activation of B-Raf. Proc. Natl. Acad. Sci. USA
104: 10465-10469
[Abstract]
[Full Text]
-
Prickett, T. D., Brautigan, D. L.
(2007). Cytokine Activation of p38 Mitogen-Activated Protein Kinase and Apoptosis Is Opposed by alpha-4 Targeting of Protein Phosphatase 2A for Site-Specific Dephosphorylation of MEK3. Mol. Cell. Biol.
27: 4217-4227
[Abstract]
[Full Text]
-
Nonn, L., Duong, D., Peehl, D. M.
(2007). Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis
28: 1188-1196
[Abstract]
[Full Text]
-
Mendoza, M. C., Booth, E. O., Shaulsky, G., Firtel, R. A.
(2007). MEK1 and Protein Phosphatase 4 Coordinate Dictyostelium Development and Chemotaxis. Mol. Cell. Biol.
27: 3817-3827
[Abstract]
[Full Text]
-
Roux, P. P., Shahbazian, D., Vu, H., Holz, M. K., Cohen, M. S., Taunton, J., Sonenberg, N., Blenis, J.
(2007). RAS/ERK Signaling Promotes Site-specific Ribosomal Protein S6 Phosphorylation via RSK and Stimulates Cap-dependent Translation. J. Biol. Chem.
282: 14056-14064
[Abstract]
[Full Text]
-
Hornsby, P. J.
(2007). Senescence As an Anticancer Mechanism. JCO
25: 1852-1857
[Abstract]
[Full Text]
-
Xue, M., Campbell, D., Jackson, C. J.
(2007). Protein C Is an Autocrine Growth Factor for Human Skin Keratinocytes. J. Biol. Chem.
282: 13610-13616
[Abstract]
[Full Text]
-
Kobayashi, T., Puro, D. G.
(2007). Loss of Insulin-Mediated Vasoprotection: Early Effect of Diabetes on Pericyte-Containing Microvessels of the Retina. IOVS
48: 2350-2355
[Abstract]
[Full Text]
-
Russell, D. L., Robker, R. L.
(2007). Molecular mechanisms of ovulation: co-ordination through the cumulus complex. Hum Reprod Update
13: 289-312
[Abstract]
[Full Text]
-
Zhi, L., Ang, A. D., Zhang, H., Moore, P. K., Bhatia, M.
(2007). Hydrogen sulfide induces the synthesis of proinflammatory cytokines in human monocyte cell line U937 via the ERK-NF-{kappa}B pathway. J. Leukoc. Biol.
81: 1322-1332
[Abstract]
[Full Text]
-
van Wijk, B., Moorman, A. F.M., van den Hoff, M. J.B.
(2007). Role of bone morphogenetic proteins in cardiac differentiation. Cardiovasc Res
74: 244-255
[Abstract]
[Full Text]
-
Suzuki, K., Wilkes, M. C., Garamszegi, N., Edens, M., Leof, E. B.
(2007). Transforming Growth Factor {beta} Signaling via Ras in Mesenchymal Cells Requires p21-Activated Kinase 2 for Extracellular Signal-Regulated Kinase-Dependent Transcriptional Responses. Cancer Res.
67: 3673-3682
[Abstract]
[Full Text]
-
Zhang, L., Yang, S.-H., Sharrocks, A. D.
(2007). Rev7/MAD2B Links c-Jun N-Terminal Protein Kinase Pathway Signaling to Activation of the Transcription Factor Elk-1. Mol. Cell. Biol.
27: 2861-2869
[Abstract]
[Full Text]
-
Gupta, V., Awasthi, N., Wagner, B. J.
(2007). Specific Activation of the Glucocorticoid Receptor and Modulation of Signal Transduction Pathways in Human Lens Epithelial Cells. IOVS
48: 1724-1734
[Abstract]
[Full Text]
-
Wang, X., Goh, C. H., Li, B.
(2007). p38 Mitogen-Activated Protein Kinase Regulates Osteoblast Differentiation through Osterix. Endocrinology
148: 1629-1637
[Abstract]
[Full Text]
-
Ebner, H. L., Blatzer, M., Nawaz, M., Krumschnabel, G.
(2007). Activation and nuclear translocation of ERK in response to ligand-dependent and -independent stimuli in liver and gill cells from rainbow trout. J. Exp. Biol.
210: 1036-1045
[Abstract]
[Full Text]
-
Ryan, K E, Casey, S M, Canty, M J, Crowe, M A, Martin, F, Evans, A C O
(2007). Akt and Erk signal transduction pathways are early markers of differentiation in dominant and subordinate ovarian follicles in cattle. Reproduction
133: 617-626
[Abstract]
[Full Text]
-
Patel, O., Dumesny, C., Shulkes, A., Baldwin, G. S.
(2007). C-Terminal Fragments of the Gastrin-Releasing Peptide Precursor Stimulate Cell Proliferation via a Novel Receptor. Endocrinology
148: 1330-1339
[Abstract]
[Full Text]